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Since the 1980s, social anxiety disorder (SAD) was recognized as a diagnostic entity (American 
Psychiatric Association, 1980). As described in DSM-IV-TR, social anxiety disorder is characterized 
by a persistent fear of one or more social or performance situations in which the person is 
exposed to people or to possible scrutiny by others. Examples of such situations are meetings, 
parties, speaking in front of an audience, or making a phone call in public. The feared situations 
are avoided or are endured with intense anxiety and distress (American Psychiatric Association, 
2000). Experiencing anticipatory anxiety and shame afterwards are characteristic of SAD. Somatic 
symptoms of anxiety that occur in social situations are palpitations, blushing, trembling and 
sweating. Two subtypes of SAD can be distinguished: the specific (sSAD) and the generalized type 
(gSAD) (American Psychiatric Association, 2000), the latter being the most disabling, most severe 
and complete subtype, showing all aspects of social anxiety. In this thesis, we chose to investigate 
gSAD, anticipating to find most pronounced neurobiological dysfunctions. 
SAD is among the most prevalent mental disorders, however, most epidemiological 
studies did not make a distinction between subtypes. Reason for this is that at first there was no 
evidence for a possible distinction, and DSM-III defined social phobia primarily as performance 
anxiety. In DSM-III-R (1987) the generalized subtype was introduced, in which the phobic situation 
included most social situations, but no additional criteria were provided.  In 1995, Manuzza et al. 
showed that generalized and non-generalized social phobia were valid subtypes, and that on a 
biological level familial social phobia was more common among patients with generalized social 
phobia (Mannuzza et al., 1995).
In European community studies, lifetime prevalence rates of 3.9 to 13.7%  according to 
DSM-IV criteria were found and more women were affected than men (Fehm et al., 2005). The 
National Comorbidity Survey Replication in the United States reported life time prevalence rates 
of 12.1% (Ruscio et al., 2008). An epidemiological survey in Ontario, Canada, did discriminate 
between the specific (sSAD) and the generalized subtype (gSAD) and reported life time prevalence 
rates of  7.0% for sSAD and 5.9% for gSAD (Stein and Kean, 2000). The prevalence estimates of 
gSAD were higher in women than in men, but no exact data were reported on this (Stein and Kean, 
2000). Symptoms of gSAD might also be more severe in women than in men. The onset of gSAD is 
often at puberty or before (Keller, 2003; Wittchen and Fehm, 2003; Stein and Kean, 2000). 
gSAD is still generally underrecognized even among psychiatrists and the effects of 
gSAD are still underestimated. The National Comorbidity Survey showed that gSAD is associated 
with impairment of social functioning, family-life and close relationships (Lampe et al., 2003; Patel 
et al., 2002; Stein and Kean, 2000; Wittchen et al., 1999). In addition, patients with gSAD are less 
likely to be in a relationship or marriage (Dingemans et al., 2001). gSAD was also associated with 
early leave of school (Stein and Kean, 2000), lower level of education (Katzelnick and Greist, 2001; 
Wittchen et al., 1999), a higher risk of being unemployed (Patel et al., 2002; Lampe et al., 2003), and 
engagement in jobs below the level of qualification (Katzelnick and Greist, 2001). Furthermore, 




without comorbid disorders but with the worst fears were least likely to receive treatment (Ruscio 
et al., 2008). 
Although gSAD is a disabling disease, only half of the patients receive treatment (Ruscio 
et al., 2008). Treatments of choice for gSAD are serotonin reuptake inhibitors (SSRIs), serotonin-
noradrenalin reuptake inhibitors (SNRIs) and cognitive behavioural therapy (CBT) (Bandelow et 
al., 2007; Ipser et al., 2008). Monoamine oxidase inhibitors (MAOIs) and benzodiazepines are also 
effective, but are regarded to be second-line agents: MAOIs, because treatment requires dietary 
and medication restrictions, and benzodiazepines, because of cognitive adverse events, addiction 
and the requirement of slow withdrawal (Ipser et al., 2008). 
Neurobiological background 
The underpinnings of the neurobiology of gSAD are not clear yet. Research in other affective 
disorders showed that several hormonal and neurotransmitter systems such as the serotonergic 
and dopaminergic neurotransmitter systems, are involved in the neurobiology of these disorders, 
as well as the stress system and female gonadal hormones, as will be described in short in the 
following section. 
The efficacy of SSRIs suggests that the neurotransmitter serotonin, regulating among 
other things mood and anxiety, might be involved in major depressive disorder, posttraumatic 
stress disorder (PTSD), generalized anxiety disorder (GAD) and panic disorder (PD) (Hoffman 
and Mathew, 2008; Vaswani et al., 2003). Dopamine, central in reward and motivation, might 
be involved in the neurobiology of PTSD, as was shown in a study in which increased excretion 
of dopamine and its metabolite were found in the urine of PTSD patients (Heim and Nemeroff, 
2009). In addition, dysregulation of the stress system, the hypothalamic-pituitary-adrenal-axis 
(HPA-axis) and autonomic nervous system (ANS), in affective disorders was reported. Cortisol, 
the major final product of the HPA-axis in humans, modulates at several levels the function of 
many neurotransmitters, including serotonin and dopamine. Hyperfunctioning of the HPA-axis 
was found in major depression, whereas in PTSD predominantly hypofunctioning was found with 
increased sensitivity of the HPA-axis to negative glucocorticoid feedback (Swaab et al., 2005; Brown 
et al., 2009; Heim and Nemeroff, 2009). Furthermore, in panic disorder, HPA-axis hyperactivity in 
response to contextual cues was reported (Abelson et al., 2007). Other studies found that baseline 
HPA-axis functioning in panic disorder was the same as in healthy controls (Strohle and Holsboer, 
2003). Hyperfunctioning of the HPA-axis was also reported in generalized anxiety disorder (GAD) 
(Mantella et al., 2008). Hyperactivity of the other branch of the stress system, the autonomic/ 
sympathetic nervous system, was described in major depression, PTSD, and might be the case in 
PD (Brown et al., 2009; Heim and Nemeroff, 2009; Grassi and Kiowski, 2002). Studies on female 
gonadal hormones reported that they affect the course and severity of several symptoms of anxiety. 
Premenstrual increase of anxiety symptoms was reported in healthy women, and exacerbation of 
psychiatric symptoms in women with depressive disorder and in women with anxiety disorders, 







Aim of the thesis
Knowledge of the neurobiology of gSAD is essential for the development of new treatments. Since 
many systems seem to be involved in the neurobiology of affective disorders, we aimed in this 
thesis to make an exploration of the serotonergic and dopaminergic systems, the two branches of 
the stress system, namely the HPA-axis and the noradrenergic system/ANS, and we did a first step 
in studying the influence of reproductive hormones in gSAD.
Introduction of the neurotransmitter and hormonal systems that were 
studied in this thesis
Serotonin (5-hydroxytryptamine = 5-HT) is a metabolite of the amino acid tryptophan. Following 
transport of tryptophan into the serotonin neuron, tryptophan is converted into 5-hydroxytryptophan 
(5HTP) by the enzyme tryptophan hydroxylase, which is the rate limiting step in the synthesis. 5HTP 
is then quickly converted into serotonin by the enzyme aromatic amino acid decarboxylase. After 
release into the synapse, the serotonin transporter regulates the availability of serotonin in the synapse 
by a reuptake mechanism. Serotonin is a regulatory neurotransmitter and is among other functions 
involved in the regulation of stress, mood, sleep, appetite, impulse control, and reproduction.
Dopamine is a catecholamine synthesized from the precursor tyrosine. The activities of 
tyrosine hydroxylase, the rate limiting step, and dihydroxyphenylalanine decarboxylase lead to 
production of dopamine. Dopamine can be metabolized by catechol-O-methyltransferase (COMT) 
or monoamine oxydase (MAO), the same enzymes involved in the metabolism of norepinephrine 
and epinephrine. Dopamine is thought to be involved in motivation, reward, reinforcement and 
motor functions and plays a poorly understood role in some sympathetic ganglia of the ANS.
Central in stress response is regulation of the hypothalamic-pituitary-adrenal axis (HPA-
as) and the ANS. Stress initiates the release of corticotrophin releasing hormone (CRH), which 
potentates the stress response by organizing the ANS response and the HPA-axis response. Thus both 
branches of the stress system are activated in times of stress, and therefore are likely to be hyperactive 
in anxiety disorders. 
HPA-axis activity is regulated by CRH and arginine-vasopressine (AVP), which are released 
in the paraventricular nucleus of the hypothalamus. They coordinate the release of adrenocorticotrope 
hormone (ACTH) by the pituitary. ACTH induces the secretion and release of cortisol in a pulsatile 
manner from the adrenal glands. Cortisol modulates at the periphery energy mobilization, the 
immune system, bone and muscle growth, epithelial cell growth, erythroid cell production and the 
cardiovascular system. In the brain cortisol influences the limbic system by binding to two receptors, 
the high affinity mineralocorticoid receptor (MR) and the low affinity glucocorticoid receptor 
(GR). The GR plays an important role in the negative feedback of the system. HPA-axis activity is 
determined by two factors: stress and the normal circadian rhythm (Lanfumey et al., 2008). Recent 
studies in healthy humans indicated that HPA-axis function in stress and in non-stressed conditions 




(Buchanan et al., 2004; Kern et al., 2008) and the prefrontal cortex (Kern et al., 2008). 
The somatic symptoms of gSAD like palpitations, blushing, trembling and sweating are 
under autonomic control. Noradrenaline is synthesized from the precursor tyrosine. In the periphery, 
the most prominent neurons that synthesize noradrenaline are the sympathetic ganglion cells of the 
Autonomic Nervous System (ANS). In the brain, noradrenaline is produced in the locus coeruleus, a 
brainstem nucleus that projects to forebrain targets, influencing sleep and wakefulness, attention, and 
feeding behaviour. The reciprocal interaction between the locus coeruleus and the paraventricular 
nucleus provides a link between both systems. One of the important receptors is the α2-adrenergic 
autoreceptor, modulating presynaptically the release of several other neurotransmitters. The ANS is 
influenced by many brain structures, mostly via the hypothalamus. The hypothalamus integrates all 
the information into a coherent pattern of autonomic response. The hypothalamus regulates the ANS 
in two ways. It projects to neurons in the brain stem and spinal cord for the control of temperature, 
heart rate, blood pressure and respiration. 
The gonadal hormones estrogen and progesterone regulate female hormonal phases and 
are also considered neuroactive steroids, because of their capacity to modify neural activities (Le 
Melledo et al., 2001; Dubrovsky, 2005). Estrogens influence the serotonergic system through the 
estrogen receptor ERβ by promoting serotonergic transmission (Osterlund et al., 2005). Progesterone 
interacts with several neurotransmitter systems, neuropeptides and the HPA-axis. It influences 
anxiety probably by its effects on the gamma-aminobutyric acid (GABA)A-receptor. The GABAA-
receptor modulates the output of for example the dopaminergic, adrenergic, and serotonergic 
systems (Le Melledo and Baker, 2004). Furthermore, sex steroids play a role in lifelong structural 
plasticity of several brain regions, including areas involved in stress response, such as the amygdala 










Outline of the thesis
In chapter 2 we describe a serotonergic challenge with rapid intravenous meta-chlorophenylpiperazine 
(m-CPP) in seven patients with panic disorder, seven patients with gSAD and seven healthy controls in 
order to confirm the involvement of serotonin in gSAD and to evaluate the possibility of a shared 
neurobiology of gSAD and panic disorder. For this study we used meta-chlorophenylpiperazine 
(m-CPP), which is a (partial) 5-HT2C receptor agonist that also possesses moderate to low affinity 
for other 5-HT receptors, as well as for (α2) adrenergic and dopamine receptors. Rapid intravenous 
administration of 0.1 mg/kg m-CPP is highly sensitive and selective in the provocation of panic 
attacks in patients with panic disorder as compared to healthy controls (Van Der Wee et al., 2004). 
It was our aim to confirm that serotonin is involved in the neurobiology of gSAD and that gSAD 
and panic disorder are neurobiologically distinct disorders.
In chapter 3 we studied the involvement of the serotonergic and dopaminergic system 
in gSAD by means of a single photon emission computed tomography (SPECT) neuroimaging 
study with 123I-ß-(4-iodophenyl)-tropane (123I-β-CIT), which binds to the serotonin and dopamine 
transporters, in twelve gSAD patients and twelve healthy controls. We used 123I-ß-CIT SPECT 
to visualize both the dopamine and the serotonin transporter in the human brain after a single 
administration of the ligand. Binding of 123I-ß-CIT in the striatal region has been shown to reflect 
mainly binding to the dopamine transporter, binding in the thalamus, midbrain and pons to reflect 
predominantly binding to the serotonin transporter (Pirker et al., 1995; De Win et al., 2005). 
The first SPECT scan was made four hours after the infusion of 123I-ß-CIT to visualize serotonin 
transporter binding, and another SPECT scan was made twenty-four hours after infusion to 
visualize dopamine transporter binding. It was our aim to find differences in the dopamine and 
serotonin transporter binding in gSAD.
Chapter 4 describes an open-label pilot study in which we investigated the efficacy of 
mirtazapine, an antidepressant blocking the α2-adrenergic autoreceptors and therefore stimulating 
noradrenergic and serotonergic pathways in gSAD. In this study fourteen gSAD patients were 
treated for twelve weeks with mirtazapine 30 mg. The primary outcome measure was the change in 
score on the Liebowitz Social Anxiety Scale (Liebowitz, 1987). We expected to find that mirtazapine 
might be an effective treatment in gSAD.
In chapter 5 we studied the involvement of the stress system in gSAD in basal (non-
challenging) conditions. We investigated the two branches of the stress system, the HPA-axis and 
the ANS, in concert in 43 gSAD patients and 43 controls in basal (non-challenging) conditions, 
and after a low dose of dexamethasone to investigate the feedback sensitivity. We used the non-
invasive markers salivary cortisol for the HPA-axis and salivary alpha-amylase (sAA) for the ANS. 
sAA is a relatively new marker for the ANS. sAA is produced by the salivary glands, primarily by 
acinar cells. Acinar cells are innervated by both the sympathetic and parasympathetic nervous 
system. The results of studies in animals and humans indicate that the ANS plays a powerful role 
in the secretion of sAA, with contributions of both the alpha-adrenergic and beta-adrenergic 
mechanisms. Therefore sAA might be regarded as a marker of autonomic activation (For a review 
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1see Nater and Rohleder, 2009). We aimed to find differences in the activation of the two branches 
of the stress system in basal non-stressed conditions in gSAD.
The interplay between the serotonergic system and the two branches of the stress system 
in gSAD was studied as described in chapter 6. Therefore the cortisol and sAA responses to a 
tryptophan depletion challenge versus a control condition combined with a public speaking 
challenge, were measured in two groups of nine gSAD patients. Acute tryptophan depletion is 
a procedure that temporarily decreases serotonergic neurotransmission (Hood et al., 2005). 
Drinking a large neutral amino-acid (LNAA) mixture without tryptophan (TRP) leads to a 
decreased plasma TRP/LNAA ratio. Since TRP and large neutral amino acids (LNAAs) compete 
for transport through the blood-brain-barrier, less TRP will be available in the brain, decreasing 
the synthesis of serotonin. This in turn diminishes the effects of SSRIs (Hood et al., 2005). It was 
our aim to find differences in the activation of the autonomic nervous system and the HPA-axis 
following stress after manipulation of the serotonergic system in gSAD.
In chapter 7 we describe a retrospective inventory of the course of gSAD symptoms 
during the female hormonal cycle to investigate whether female gonadal hormones are likely to be 
involved in the neurobiology of gSAD. Female gSAD patients completed a self-report survey with 
questions regarding the menarche, menstrual cycle, oral contraceptive use, pregnancy, lactation, 
postpartum period and menopause. Women that did report an influence of these phases on gSAD 
symptoms were asked to rate the severity of gSAD symptoms in these variable hormonal phases. 
We aimed to find that the fluctuations of female reproductive hormones might influence symptoms 
of gSAD in women.
The summary, conclusions and discussion of this thesis will be presented in chapter 8, 
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Behavioural effects of rapid 
intravenous administration of meta-
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panic disorder and healthy controls
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Findings from epidemiological, pharmacotherapeutical, genetic and neurobiological studies 
suggest a possible overlap in the neurobiology of generalized social anxiety disorder (gSAD) 
and panic disorder (PD). Previously we have found a rapid intravenous m-CPP challenge of 0.1 
mg/kg to be highly sensitive and selective in the provocation of panic attacks in patients with 
PD. We therefore directly compared the behavioural, neuroendocrine and physiological effects 
of this rapid m-CPP challenge in a small sample of patients with gSAD, patients with PD and 
matched healthy controls. Panic attacks were significantly more provoked in patients with PD 
(85%), but not in patients with gSAD (14%) as compared to healthy controls (0%). Effects on 
the other behavioural parameters, but not on the neuroendocrine and physiological parameters, 
were significantly greater in patients with PD compared to patients with gSAD and controls. Our 
preliminary data do not support a shared neurobiology of gSAD and PD. 
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Introduction
Generalized social anxiety disorder (gSAD) and panic disorder (PD) are among the most prevalent 
anxiety disorders, with reported lifetime prevalences in Europe of 2.4% for SAD and of 2.1% for 
PD (Alonso et al., 2004a).  In the United States lifetime prevalences of 3.4% for PD and 13.3% for 
SAD were found (Sheikh et al., 2002; Magee et al, 1996). PD and gSAD may cause severe social, 
occupational and academic impairment and typically have a chronic course. Although the two 
disorders clearly have a different core phenomenology, with spontaneous panic attacks occurring 
in PD and fear of scrutiny by others in gSAD, data from epidemiological, pharmacotherapeutical, 
genetic as well as a variety of neurobiological studies suggest an overlap in the neurobiology of 
gSAD and PD. 
In epidemiological studies gSAD and PD are usually found to be highly comorbid 
conditions. Thus, in the European Study of the epidemiology of mental disorders (ESEMeD) the 
12-month pair wise association between SAD and PD expressed in odd ratio’s was 11.6 (Alonso et 
al., 2004b). Comparable to these findings in adult populations, the results of a recent large study 
in pre-adolescents indicated that, in a general population sample, it may not be useful to discern 
children with different types of anxiety symptoms (Ferdinand et al., 2006).
Pharmacotherapeutical studies have shown the efficacy of the selective serotonin reuptake 
inhibitors (SSRIs) in gSAD and PD, implicating the involvement of the serotonergic system in both 
disorders. However, tricyclic antidepressants and alprazolam have been found to be less effective 
in gSAD than in PD (Blanco et al., 2003; Kasper and Resinger, 2001; Zohar and Westenberg, 2000). 
At large, genetic studies seem to point at an anxiety diathesis model, i.e. a genetic predisposition 
to develop anxiety related symptoms and anxiety disorders. There seem to be genes that increase 
the risk only for specific disorders, as well as genes that increase the risk for anxiety disorders in 
general (Villafuerte and Burmeister, 2003; Hettema et al., 2005). Neuroimaging studies have shown 
the involvement of the same fear-circuitry in PD and in gSAD, but some differences have been 
found, notably in the involvement of elements of the dopaminergic system (Kent and Rauch, 2003; 
Charney, 2003).
A large number of studies on the neurobiology of gSAD and PD has employed challenge 
paradigms with anxiogenic or panicogenic pharmacological agents, often resulting in more or 
less comparable behavioural effects in patients with PD and patients with gSAD. However, only a 
small number of these studies directly compared the effects of the panicogenic challenge in patients 
with PD, patients with gSAD and matched healthy controls (Gorman et al., 1990; Papp et al., 1993; 
Caldirola et al., 1997; McCann et al., 1997; Tancer et al., 1994). We studied the effects of the rapid 
intravenous administration of 0.1 mg/kg meta-chlorophenylpiperazine (m-CPP), a (partial) 5-HT2c 
receptor agonist that also possesses moderate to low affinity for other 5-HT receptors, as well as for (α2) 
adrenergic and dopamine receptors. We found this rapid intravenous m-CPP challenge to be highly 
sensitive and selective in the provocation of panic attacks in patients with PD as compared to healthy 
controls (panic attacks were provoked in 90% of the controls and in 0 % of the healthy controls) (Van 







gSAD and PD by directly comparing the behavioural, neuroendocrine and physiological effects of 
the rapid intravenous administration of 0.1 mg/kg m-CPP in patients with gSAD, patients with PD, 
and matched healthy controls.
Experimental procedures
Subjects
Seven patients (five males, two females) with gSAD, seven patients with PD with or without 
agoraphobia and seven healthy controls participated in this study. Subjects were pair wise matched 
for sex, and group-wise on age. The diagnosis was made according to DSM-IV criteria, no axis I and 
no major axis II comorbidity was allowed and the diagnosis was confirmed by the Mini International 
Neuropsychiatric Interview Plus 5.0.0 (Sheehan et al., 1998; Van Vliet and De Beurs, 2007). In 
addition, no life time comorbidity between PD and gSAD was allowed. Subjects had no clinically 
significant medical disorders, were drug free for minimal 2 weeks (60 days for fluoxetine, six months 
for corticosteroids), had not donated blood during the 60 days preceding the test day, female 
subjects were not pregnant or breast-feeding, and all subjects had normal physical and laboratory 
examinations. There were no subjects with a history or suspicion of substance abuse. Subjects using 
drugs of abuse or more than 6 cups of coffee, 15 cigarettes or 3 units of alcohol a day, were excluded. 
The study was performed in the outpatient clinic of the University Medical Center Utrecht, the 
Netherlands, and was approved by the Medical Ethical Committee of the University Medical Center 
Utrecht. All subjects gave written informed consent prior to inclusion in the study.  
Procedures
We used the same single blind, comparative design, as in our previous study (Van Der Wee et al., 
2004). Subjects were told that they would receive either m-CPP or a solution mimicking some of 
the side-effects of m-CPP (i.e. hot and cold flushes and dizziness). In reality all subjects received 
m-CPP. Subjects took a light breakfast at least one hour before the test. Coffee, smoking and alcoholic 
beverages were not allowed from 9 p.m. on the evening before. Immediately after baseline assessments 
an indwelling intravenous catheter was placed in a forearm vein in each arm at 9.00 a.m. At 10.00 a.m. 
m-CPP (0.1 mg/kg diluted in 20 ml of normal saline) was administered in 90 seconds by means of an 
automatic pump (Becton Dickinson). Behavioural, physiological and neuroendocrine responses, as 
well as m-CPP plasma levels were measured immediately before infusion and at 30-minutes intervals 
until 150 minutes after infusion. 
Behavioural assessments
Behavioural responses were measured prior to the measurement of physiological and neuroendocrine 
responses. Behavioural responses were assessed by using a Visual Analogue Scale (VAS) for anxiety 
and the Panic Symptom Scale (PSS) (Bradwejn et al., 1992; Van Megen et al., 1994; Van Megen et al., 
1996). The VAS for anxiety was used to evaluate the change in anxiety, with a score range from 0 = 
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not at all to 100 = most ever. The PSS is a self-rating instrument derived from DSM-III-R criteria for 
a panic attack. Both the symptom severity and the fear of the symptom are rated on a 5-point scale 
(0 = not at all to 4 = severe). 
After the challenge the occurrence of panic attacks (the main outcome measure) was assessed. A 
panic attack had to fulfil the following criteria: subjects had to experience a feeling of panic, had to 
have an increase of at least four of the 13 DSM-IV symptoms of a panic attack, as extracted from 
the PSS, combined with a score of two or more on the item ‘Apprehension’ of these four symptoms. 
Subjects had to report that the panic attack was similar to their spontaneous ones when applicable.
Vital signs
Temperature (orally measured), systolic and diastolic blood pressure (supine after 5 minutes rest; 
standing after 1 minute standing), and heart rate (supine after 5 minutes rest; standing after 1 
minute standing) were recorded. Blood pressure and heart rate measurements were assessed with a 
completely automated device consisting of an inflatable cuff and an oscillatory detection system. All 
values were registered on a built-in recorder so that measurements are observer-independent. 
Neuroendocrine parameters
Neuroendocrine measurements consisted of assessment of cortisol and growth hormone (GH) levels. 
Cortisol was measured using a competitive, chemiluminscent assay (ACS: Centaur Cortisol, Chiron 
Diagnostics Corporation, East Walpole, MA, USA). The intra-assay and inter-assay coefficients of 
variation at 4 μg/ml were 4% and 6% respectively. GH was assayed using a commercially available 
radio-immunoassaykit (Oris Industry Company, Gif-sur-Yveth, France), with a lower limit of 
detection of 0.5 mU/l and an intra- and interarray coefficient of variation of 8 and 11% respectively. 
Pharmacokinetics
M-CPP was kindly provided by Janssen Pharmaceuticals. M-CPP plasma levels were taken 30, 60, 
90, 120 and 150 minutes after m-CPP administration, and analysed using a high-performance liquid 
chromatography procedure as described by Suckow et al. (1990) and slightly modified to the use of 
an electrochemical detector.
Statistics
Since the data were not normally distributed, non-parametric statistics were used. The rate of panic 
attacks in the three groups following the administration of m-CPP was compared using a Fisher’s 
exact test for three groups, followed by Fisher’s exact tests for two groups when a significant result 
was obtained. P-values were Bonferroni corrected for multiple comparisons.
Delta scores (∆, defined as the maximum change from baseline) were calculated for the 
PSS, for the VAS anxiety and for cortisol and GH. Delta scores and age and peak levels of m-CPP for 
the three groups were first analysed with a Kruskal-Wallis test, followed by Mann-Whitney U tests 
when a significant result was obtained. A non-significant result from the Kruskal-Wallis tests for a 







of any effect of the m-CPP administration. Therefore, in the case of a non-significant result from 
the Kruskal-Wallis test, a post-hoc Friedman test was performed to assess that there had been an 
effect of m-CPP on this specific parameter over time. 
Results
The three groups did not significantly differ in age (p=0.786; gSAD mean age 40.9 years ± 14.6; PD 
39.0 ± 8.8; Co 37.1 ± 7.8). We found no differences in peak m-CPP levels (p=0.573;  gSAD mean 43.0 
ng/ml ± 24.9; PD 44.2 ± 11.9; Co 36.4 ± 10.4). Six out of seven PD patients (85 %), one out of seven 
gSAD patients (14%) and none of the healthy controls experienced a panic attack following the 
rapid intravenous administration of m-CPP. This was a highly significant between group difference 
(Fisher’s exact test, p=0.003). Fisher’s exact tests on two groups showed a significant difference in 
panic attack rate between gSAD and PD (p=0.045, Bonferroni corrected) and between PD and 
controls (p=0.006, Bonferroni corrected), but not between gSAD and controls (p=1.5, Bonferroni 
corrected). 
Analysis of the ∆ PSS total score and the ∆ VAS anxiety with a Kruskal-Wallis test yielded 
a significant difference for the ∆ PSS total score (p=0.001) and for the ∆ VAS anxiety (p=0.047). 
Post-hoc analysis with Mann-Whitney U tests showed significant differences on the ∆ PSS total 
score between gSAD and PD (p=0.017), between gSAD and controls (p=0.038), and between PD 
and controls (p=0.001). The PD group showed the highest ∆ PSS score and the control group the 
lowest. For details see Figure 1, and Tables 1 and 2.
 
Figure 1 PSS total scores after m-CPP administration. gSAD is generalized social anxiety disorder, PD is panic dis-
order and Co is controls. M-CPP is administered at t=0.
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Post-hoc analysis on the ∆ VAS anxiety showed significant differences between PD and 
controls (p=0.038) and almost reached significance between gSAD and controls (p=0.053). No 
significant difference was found on the ∆ VAS anxiety between PD and gSAD (p=0.383). For details 
see Tables 1 and 2. In one patient with gSAD who experienced no panic attack, blood could not be 
obtained at all time points. This patient was not included in the analysis of the neuro-endocrine 
parameters and the closest match for sex and age in the other groups was removed by a researcher 
blinded for the results of the assessments (I.V.). The Kruskal-Wallis test showed a significant difference 
for ∆ growth hormone (p=0.042), but not for ∆ cortisol (p=0.371). ∆ GH responses were significant 
different between gSAD and PD (p=0.015), but not between both patient groups and controls. Of the 
three groups the gSAD group had the highest ∆ GH levels after m-CPP administration and the PD 
group the lowest, with the controls in between. For details see tables 1 and 2.
Post-hoc Friedman test for cortisol levels showed a significant effect of m-CPP 
administration on cortisol levels (p=0.000). For details see Tables 1 and 2.
We found no differences between the three groups in changes in the physiological parameters.
Table 1 Mean ∆ scores and standard deviation after m-CPP administration of PSS total score, VAS 
anxiety, growth hormone and cortisol
gSAD PD Co p (KW)
Δ PSS total score 33.9 ± 20.9 75.1 ± 31.2 15.4 ± 8.1 0.001*
Δ VAS anxiety 31.6 ± 25.4 46.1 ± 32.1 12.7 ± 25.9 0.047*
Δ GH (mU/l) 23.1 ± 20.0 8.8 ± 9.0 7.6 ± 9.4 0.042*
Δ Cortisol (μg/ml) 0.15 ± 0.12 0.23 ± 0.14 0.26 ± 0.14 0.371
gSAD is social anxiety disorder, PD is panic disorder and Co is controls. PSS is the Panic Symptom Scale rating the 
presence of a symptom and the fear provoked by a symptom. VAS is the Visual Analogue Scale for anxiety. GH is 
growth hormone. For all comparisons a Kruskal-Wallis (KW) test was used.  Δ is the difference between the baseline 
value and the maximum value after m-CPP administration. Mean Δ scores and standard deviation are given instead 
of medians or mean ranks, in order to give better insight in the data. P-values are presented uncorrected for multiple 
comparisons.
Tabel 2 P-values of post-hoc Mann-Whitney U tests of Δ PSS total scores, Δ VAS anxiety, and Δ GH.
p p p
gSAD : PD gSAD : Co PD : Co
Δ PSS total score 0.017* 0.038* 0.001*
Δ VAS anxiety 0.383 0.053 0.038*
Δ GH 0.015* 0.138 0.805
gSAD is generalized social anxiety disorder, PD is panic disorder and Co is controls. PSS is the Panic Symptom Scale 
rating the presence of a symptom and the fear provoked by a symptom. VAS is the Visual Analogue Scale for anxiety. 
GH is growth hormone. For post-hoc 2x2 comparisons a two-tailed Mann-Whitney U test was used. P-values are 








Using a rapid i.v. m-CPP challenge we found a different behavioural and neurobiological response 
in gSAD and PD.  The challenge resulted in a high frequency of panic attacks and high PSS 
scores in the PD group, while the gSAD group experienced panic attacks in a very low frequency, 
comparable to the controls. 
Our results differ from findings in previous studies comparing the effects of panicogenic 
challenges in gSAD and PD. Several anxiogenic challenges, like 35% CO2, pentagastrin and 
caffeine, did not show significant differences in the occurrence of panic attacks between gSAD 
and PD (Caldirola et al., 1997; Gorman et al., 1990; McCann et al., 1997; Tancer et al., 1994). In 
other panicogenic challenges with 5% CO2, 35% CO2, lactate infusions and hyperventilation, the 
gSAD group showed less panic attacks than the PD group, but more than the control group when 
a control group was available (Holt and Andrews, 1989; Liebowitz et al., 1985; Papp et al., 1993). 
Some studies also employed scales to measure the provoked levels of anxiety. In these studies, with 
pentagastrin, caffeine and 35 % CO2, no differences in anxiety ratings were found between gSAD 
and PD (Caldirola et al., 1997; Gorman et al., 1990; Tancer et al., 1994). Only in a challenge study 
with 35 % CO2, a  pattern similar to the one found in our study was found, with anxiety levels being 
the highest in PD, intermediate in gSAD and the lowest in the control group, although this effect 
reached significance only when sex was not part of the analysis (Papp et al., 1993). 
Neuroendocrine measures were only included in a few studies examining pharmacological 
panicogenic challenges in gSAD, with unequivocal results. Thus, following a pentagastrin 
challenge, no differences among groups (gSAD, PD and controls) in cortisol responses were 
found (McCann et al., 1997). However, after an (orally administered) m-CPP challenge, female 
patients with gSAD showed more robust cortisol responses than female controls (Hollander et al., 
1998). After the administration of caffeine, differences were found between the cortisol and lactate 
responses in patients with gSAD, patients with PD and healthy controls. The cortisol response 
was the highest in PD and the lowest in controls, with the response in gSAD being intermediate. 
The lactate response was also the highest in PD patients, but lowest in gSAD, with the controls in 
between (Tancer et al., 1994).
A challenge with clonidine resulted in blunted GH responses in gSAD and PD as 
compared to controls (Tancer et al., 1993). In the present study we found an augmented GH 
response to m-CPP in gSAD compared to PD, with the control group in between. However, GH 
levels may be difficult to interpret because of the pulsatile secretion and the possible confound of 
the occurrence of nausea, a common effect of m-CPP. 
The present study suffers from some limitations. We did not use a placebo-controlled 
design. However, to minimize the occurrence of spontaneous panic attacks, subjects were given 
the impression that they might also receive a saline solution mimicking the initial effects of m-CPP. 
Moreover, in previous placebo-controlled challenge studies in patients with gSAD and PD at our 
center, using the same type of experimental procedure, a placebo response of 0 % was found (Van 
Megen et al., 1994; Van Vliet et al., 1997). All other placebo-controlled m-CPP challenge studies 
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in patients with PD also found placebo responses of 0 % (Charney et al., 1987; Germine et al., 
1994; Kahn et al., 1988; Klein et al., 1991; Wetzler et al., 1996). These findings suggest that the 
panicogenic effect of the experimental procedure itself is very small.  
Behavioural assessments were made at 30 minutes intervals and for the first 30 minutes 
interval following the i.v. m-CPP administration retrospectively. In view of the time of onset and 
duration of symptoms a shorter interval, i.e. ten minutes, would have been more appropriate for 
behavioural assessments during the first hour after i.v. m-CPP administration. 
Our neuroendocrine assessments consisted only of cortisol and growth hormone. We did 
not assess prolactin, which might be a more reliable index of 5-HT stimulation. In the present study 
the differences in cortisol responses to the m-CPP challenge failed to reach statistical significance, 
probably as a result of a ceiling effect occurring with higher plasma levels of m-CPP.
Like several other challenge studies in PD, our study had a drug free period of at least two 
weeks. Several patients were off medication for a longer period of time. As a drug free period of 
two weeks may be too short to allow for a complete readaptation of the receptors after long-term 
antidepressant treatment, this may be a potential confounding factor
Finally, our design did not allow for a separation between biochemically and cognitively 
mediated effects of our rapid i.v. m-CPP administration.  As i.v. m-CPP is known to cause 
symptoms like light-headedness, nausea and hot and cold flushes in healthy controls, part of its 
effects in panic disorder might be attributable to cognitive factors like the misinterpretation of 
bodily symptoms (Austin and Richards, 2001). However, after the rapid i.v. administration of 
m-CPP most somatic symptoms were present to a minimal extent in controls and in the gSAD 
group. Furthermore, several somatic symptoms were only reported by the patients with PD.
Although preliminary, our data support a distinction between gSAD and PD on a 
neurobiological level and confirm that panic attacks following the rapid i.v. 0.1 mg/kg m-CPP 
challenge test combine high sensitivity and selectivity for PD.  Future research should replicate our 
findings in a larger sample size and in a placebo-controlled, double-blind design. It will also be 
important to conduct comparative studies of PD versus gSAD with a subtyping of gSAD patients 
in panic or non panic type, to evaluate whether a history of panic attacks or the diagnostic category 
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There is circumstantial evidence for the involvement of serotonergic and dopaminergic systems 
in the pathophysiology of social anxiety disorder. In the present study, using SPECT imaging, we 
examined the 123I-ß-(4-iodophenyl)-tropane binding potential for the serotonin and dopamine 
transporter in patients with a generalized social anxiety disorder and age- and sex- matched 
healthy controls. Methods: Twelve psychotropic medication-naïve patients with social anxiety 
disorder, generalized type (5 women and 7 men) and 12 sex- and age- matched healthy controls 
were studied. Volumes of interest were constructed on MRI-coregistered SPECT scans. Binding 
ratios were compared using the Mann-Whitney U test. Possible correlations between binding 
patterns and symptomatology were assessed using the Spearman rank correlation coefficient. 
Results: Significantly higher binding potentials were found for the serotonin transporter in the left 
and right thalamus of patients. Patients had also a significantly higher binding potential for the 
dopamine transporter in the striatum. Conclusion: The present study provided direct evidence for 
abnormalities in both the dopaminergic and the serotonergic systems in patients with generalized 
social anxiety disorder.
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Introduction
Social anxiety disorder (also known as social phobia) is a disabling condition that afflicts a 
large part of the general population. It tends to run a chronic and unremitting course and often 
leads to the development of alcoholism and depression. The essential feature of social anxiety 
disorder is the fear of being evaluated by others with the expectation that such an assessment 
will be negative and embarrassing. Social anxiety disorder has been subdivided into two 
subtypes. The first subtype, referred to in the DSM-IV (American Psychiatric Association, 1994) 
as ‘generalized’ social phobia, involves fear of a broad array of social situations. The second 
subtype, referred to as discrete or specific social anxiety disorder, is usually confined to one or 
two performance situations, of which public speaking is the most common (Westenberg, 1998). 
Given the clinical importance of social anxiety disorder, the neurobiology of this condition has 
received little attention to date.
Treatment studies demonstrating that selective serotonin reuptake inhibitors (SSRIs) 
and monoamine oxidase inhibitors are effective in social anxiety disorder hint that serotonergic 
and catecholaminergic pathways have a role, but these findings can be only a rough guide in 
determining the neurobiology. Challenge tests with fenfluramine and m-chlorophenylpiperazine 
have provided other circumstantial evidence for the role of serotonin (5-hydroxytryptamine or 
5-HT) in social anxiety disorder (Tancer et al., 1994; Hollander et al., 1998).  An involvement 
of the dopaminergic system in social anxiety was suggested by findings that homovanillic acid 
levels in cerebrospinal fluid tended to be lower in panic disorder patients with comorbid social 
anxiety disorder than in those without (Johnson et al., 1994). Moreover, the prevalence of social 
anxiety disorder is increased in patients in whom Parkinson’s disease develops (Stein et al., 
1990).  More recently, two neuroimaging studies have provided direct evidence that dopamine 
systems may play a role in the neurobiology of social anxiety disorder. Using 123I-labeled 
2-ß-carbomethoxy-3-ß-(4-iodophenyl)-tropane (123I-ß-CIT) as a tracer and SPECT, Tiihonen 
et al. found that the density of the dopamine transporter (DAT) in the striatum was reduced in 
patients with generalized social anxiety disorder (Tiihonen et al., 1997). Schneier et al., using 
123I-iodobenzamide SPECT, found a reduced dopamine D2 binding potential in this psychiatric 
condition (Schneier et al., 2000). Although neuroimaging studies potentially could also provide 
direct evidence for a role of serotonergic systems in social anxiety disorder, to our knowledge 
only one such study has been published to date (Lanzenberger et al., 2007). In this study, by 
Lanzenberger et al., 5-HT receptor 1A binding in several limbic and paralimbic areas was found 
to be reduced in social anxiety disorder. 
123I-ß-CIT SPECT can be used to visualize both DAT and 5-HT transporter (5-HTT) in 
the human brain after a single administration of the ligand. Binding of 123 I-ß-CIT  in the striatal 
region has been shown to reflect mainly binding to DAT; binding in the thalamus, midbrain, 
and pons reflects predominantly binding to 5-HTT (Pirker et al., 1995; De Win et al., 2005). The 
binding to DAT and 5-HTT can be further differentiated by using the difference in time course 







study, we used this approach to investigate DAT and 5-HTT binding potentials in right-handed 
psychotropic medication-naïve patients with generalized social anxiety disorder (according to 
DSM-IV criteria) and no comorbidity and in healthy controls matched pair wise by age, sex, and 
handedness. We expected the binding pattern of 123 I-ß-CIT to reflect abnormalities at the level 
of both 5-HTT and DAT.
Materials and Methods
Subjects
The study was approved by the ethics committee of the University Medical Center, Utrecht, The 
Netherlands, and was performed in accordance with the ethical standards of the declaration 
of Helsinki. After a complete description of the study had been provided to the subjects, 
written informed consent was obtained. The patients came from direct physician referrals to 
our specialized anxiety clinic or reacted to advertisements. Healthy controls were enrolled 
through advertisements in flyers and newspapers or obtained from an existing database. Only 
subjects without a lifetime history of psychosis, substance abuse, recurrent major depression, 
bipolar disorder, eating disorders, other anxiety disorders, tics, and stuttering were included. All 
participants had no lifetime history of illnesses with possible central nervous system sequelae 
and were in good physical health, as confirmed by physical and laboratory examinations. 
Subjects consumed fewer than 6 cups of coffee and 3 units of alcohol a day and smoked fewer 
than 6 cigarettes a day. Screening for current and prior adult psychopathology was done by 
administering the Mini International Neuropsychiatric Interview Plus, version 5.0.0 (Sheehan 
et al., 1998). Diagnoses were confirmed by an experienced clinician.  In addition, the Liebowitz 
Social Anxiety Scale (LSAS) was used to assess the severity of the social anxiety symptoms at 
entry (Heimberg et al., 1999). Handedness was determined by administering the Edinburgh 
Handedness Scale (Oldfield, 1971). 
 Subjects were excluded when they had a score of more than 13 on the 17-item 
Hamilton Depression Rating Scale (Hamilton, 1967). Subjects underwent imaging within 
2 weeks after inclusion.  Any cognitive behavioral therapy had been terminated at least 3 
months before the study.
Twelve patients and 12 controls were enrolled. All subjects completed the study. The patients 
and controls were perfectly matched for sex and did not differ significantly in age and 
handedness. Demographic and clinical characteristics are shown in Table 1.
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Mean age ± SD (y) 39.4 ± 12.6 33.0 ± 9.5
Total Edinburgh 0.95 ± 0.04 0.96 ± 0.03
Handedness Scale
Men (n) 7 7
Women (n) 5 5 
Nonsmokers (n) 9 8 
Length of illness (y) 23.9 ± 14.7 
Total LSAS score 73.6 ± 13.7
Total Hamilton Depression 8.3 ± 2.1
Rating Scale 
Image acquisition and analysis
Images were acquired and analyzed using the same methods as in our previously reported study 
on patients with obsessive-compulsive disorder (Van der Wee et al., 2004).  On the first day of 
scanning, the subjects received an intravenous injection of approximately 150 MBq of 123I-ß-CIT 
(MAP Medical Technologies; radionuclidic purity [125I /123I] of at least 9,5 x 10-3 at calibration 
time and a radiochemical purity of at least 95 %). We used a Prism 3000 triple-head γ-camera 
(Picker) with ultra-high-resolution fanbeam collimators and a full width at half maximum of 
approximately 12 mm. Four hours after the injection, the first scan was made to assess binding 
to 5-HTT. Between 22 and 24 hours after the injection, the second scan was obtained to measure 
binding to DAT (Kuikka et al., 1995; Laruelle et al., 1994; Willeit et al., 2000). The subjects refrained 
from coffee and nicotine in the 6-10 hours preceding each SPECT scan. Immediately after the first 
scan, the subjects received 20 mg of paroxetine to displace the 123I-ß-CIT  from 5-HTT, so that 
binding to DAT could be determined more precisely (Kuikka et al., 1995). Several studies have 
demonstrated that at modest dosages (e.g. 10 mg) of  paroxetine and other potent 5-HT reuptake 
blockers,  occupation of 5-HTT is already virtually maximal (Pirker et al., 1995; Tauscher et al., 
2001; Meyer et al., 2001). To control for possible differences in metabolism between subjects, we 
chose a higher oral dose of 20 mg. The 20-mg dose of paroxetine was well tolerated by all subjects. 
During scanning, subjects were supine with eyes and ears open and head fixed in a head holder. We 
ensured that the patients stayed awake and did not move.  For an accurate determination of each 
subject’s volumes of interest (VOIs), all subjects also underwent structural MRI (3-dimensional 
fast field echo; echo time/ repetition time, 4.6/30 ms; flip angle, 30º; field of view, 256 x 256 mm; 
matrix, 128 x 128 x 130 mm; slice thickness, 2 mm) 2 hours before the injection of 123I-ß-CIT. The 
MRI scans were reoriented to the standardized coordinate system of the Montreal standard brain 
(Collins et al., 1994). VOIs were delineated manually on the reoriented MRI scans by a researcher 
who was unaware of the subject’s identity and diagnosis, by means of the display software from 







the focus of our study was putative abnormalities at the level of 5-HTT in Social Anxiety Disorder, 
the VOIs for 5-HTT included the left and right thalamus and the midbrain/pons region, whereas 
we limited the VOI for DAT to the left and right striatum taken together.  Furthermore, this choice 
allowed a direct comparison of DAT findings with the previous study of Tiihonen et al. (Tiihonen 
et al., 1997).  We planned an exploratory posthoc analysis in which left and right striatal subregions 
would be delineated in cases in which the ROI striatum showed a significant difference between 
patients and controls. The cerebellum was used as a reference region, representing the nonspecific 
binding for 123I-ß-CIT. 
To allow exact coregistration of MRI and SPECT scans, we used fiducial markers.  Fiducial 
markers were cone-shaped, with cross-shaped feet, and were placed on the nose bridge and 
preauricular above the mandibular joints. The position of each marker was indicated with four dots 
on subject’s skin to allow for repositioning of markers immediately before the SPECT scans. Vitamin 
A and 57Co were used as contrast agents for the MRI and SPECT scans, respectively. The energy was 
set at a peak of 160 keV with a window of 20% for 123I-ß-CIT and at a peak of 120 keV with a window 
of 15% for 57Co.  After standard processing, brain SPECT images were resliced to isotropic voxels 
with dimensions of 2 mm and further treated as 3D volumes to coregister within the 3-dimensional 
orientation of the MRI scans. Coregistration was performed semiautomatically and was based on the 
position of the fiducial markers, using the Register multimodality software package and additional 
software developed at the Brain Imaging Center of the Montreal Neuroimaging Institute (MacDonald, 
1993). The researcher performing the coregistration was unaware of subject identity and diagnosis. 
For each separate VOI, the ratio of specific binding of 123I-ß-CIT to 5-HTT or DAT was 
calculated according to methodology used in previously published 123I-ß-CIT studies: the average 
radioactivity count per voxel per VOI minus the average radioactivity count per voxel in the 
cerebellum, divided by the average radioactivity count per voxel in the cerebellum.
Statistical analysis
Age was compared using the Student t test. The interrater and intrarater reliability for VOI registration 
was assessed by calculating the intraclass correlation coefficients according to the method published 
by Bartko and Carpenter (Bartko and Carpenter Jr., 1976). The specific binding ratios for 123I-ß-CIT 
were compared using the Mann-Whitney U test. For 5-HTT binding ratios in the midbrain/pons 
region and in the left and right thalamus were assessed; for  DAT binding the ratio in the striatum 
was assessed. Spearman rank correlation coefficients were calculated to assess correlations between 
specific binding ratios and LSAS scores. Two-tailed significance is reported throughout. Bonferroni 
correction for multiple comparisons (four regions of interest) yielded an adjusted P value of p < 
0.0125
Results
The intraclass correlation coefficients for the interrater and the intrarater reliability procedure 
for determining VOIs were between 0.86 and 0.99 (mean ± SD, 0.95 ± 0.05) and 0.61 and 0.98 
39
Serotonin and dopamine transporter binding
3
(mean, 0.81 ± 0.14), respectively. In one patient, only the 5-HTT uptake could be calculated, the 
last SPECT scan could not be reliably coregistered to the MRI scan because of motion artifacts. 
The VOIs for the cerebellum were 104,208 ± 16,211 mm3 for patients and 93,943 ± 11,445 
mm3 for controls. The VOIs for the midbrain/pons regions were 6,441 ± 1,370 mm3 for patients 
and 6,127 ± 1,455 mm3 for controls. The VOIs for the right thalamus were 3,962 ± 855 mm3 for 
patients and 4,544 ± 1,678 mm3  for controls, and the VOIs for the left thalamus were 4,051 ± 914 
for patients and 4,610 ± 686 mm3 for controls. The VOIs for the right caudate were 3,142 ± 519 
mm3 for patients and 2,933 ± 608 mm3 for controls, and the VOIs for the right putamen 2,064 
± 407 mm3 for patients and 1,990 ± 497 mm3 for controls. The VOIs for the left caudate were 
2,899 ± 598 mm3 for patients and 3,181 ± 573 mm3 for controls, and the VOIs for the left putamen 
were 2,022 ± 478 mm3 for patients and 2,064 ± 407 mm3 for controls. There were no significant 
differences in the sizes of the delineated VOIs between patients and controls.
There were no significant differences in the normalized binding in the reference region 
between patients and controls; normalized cerebellar counts at four hours were 20.38 ± 3.70 in 
controls and 20.90 ± 4.12 in patients and at 22-24 hours the counts were 3.75 ± 1.15 in controls 
and 3.37 ± 1.02 in patients.
The Mann-Whitney U test revealed that the average binding ratio for 5-HTT in the left 
and right thalamus was significantly higher in patients than in matched healthy controls (P = 
0.001) (Fig. 1).
Figure 1. Binding ratios for 5-HTT in left and right thalamus of psychotropic medication-naïve patients with genera-
lized social anxiety disorder (N = 12) and age- and sex-matched controls (N = 12) measured with 123I-ß-CIT SPECT. 
* P = 0.001; 2-tailed Mann-Whitney U test.
No significant differences were found in the midbrain/pons region.  The average binding 
ratio for DAT in the striatum was significantly higher in patients than in matched controls (P = 
0.011) (Fig. 2).















Figure 2. Binding ratios for the DAT in striatum of psychotropic medication-naïve patients with generalized social 
anxiety disorder (N = 12) and age- and sex-matched controls (N = 12) measured with 123I-ß-CIT SPECT. * P = 0.011; 
2-tailed Mann-Whitney U test.
The binding ratios for 5-HTT and DAT in the regions of interest in patients and controls 
are summarized in Table 2. No significant correlations were found between LSAS score and DAT 
or 5-HTT binding potential in patients. 
We performed an exploratory post-hoc delineation and analysis for right and left striatum 
and for left and right putamen and caudate. This analysis revealed that DAT binding in the right 
putamen was significant higher in patients than in matched healthy controls at a significance level 
uncorrected for multiple comparisons (P = 0.012).
Table 2  Average Binding Potentials for DAT and 5-HTT in Study Population. 
VOI Patients (N =12) Controls  (N=12) P (Mann-Whitney U test)
5-HTT 
Left thalamus 1.79 ± 0.12 1.52 ± 0.65 0.001 *
Right thalamus 1.85 ± 0.19 1.53 ± 0.19 0.001 *
Midbrain/pons 0.94 ± 0.10 0.90 ± 0.19 0.713
DAT 
Striatum 7.30 ± 0.98 5.47 ± 1.37 0.011 *
* Value survived Bonferroni correction for multiple comparisons implying 4 regions of interest.
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Discussion
We found significantly higher 123I-ß-CIT  binding ratios in the left and right thalamus  (specific 
for 5-HTT) and in the striatum (specific for DAT) of psychotropic medication-naïve patients with 
generalized social anxiety disorder with no comorbid diagnosis, relative to the findings in healthy 
controls pair wise matched for age, sex, and handedness. No abnormalities in binding ratios to the 
5-HTT-rich midbrain/pons region were found. No significant correlations were found between 
5-HTT and DAT binding ratios and scores on the symptom rating scale (LSAS).
To our knowledge this was the first study examining 123I-ß-CIT  binding ratios both  to 
5-HTT-rich regions and to DAT-rich regions in patients with generalized social anxiety disorder. 
Our finding of an altered 5-HTT binding potential in the thalamus provides a direct indication 
that 5-HT has a role in the pathophysiology of generalized social anxiety disorder. Converging data 
have implicated a network of brain regions, including the prefrontal cortex, striatum, thalamus, 
and amygdale, in the pathophysiology of generalized social anxiety disorder (Stein et al., 
2002; Mathew et al., 2001).  Most regions of this putatively involved network in social anxiety 
disorder are densely innervated by serotonergic or dopaminergic neurons. Impaired striatal-
thalamic filtering of information relevant for social evaluation and an excessive conditionability 
of striatal-amygdalal circuits may play a central role in the pathophysiology of social anxiety 
disorder (Li et al., 2001). 
Our finding of higher binding potentials of 123I-ß-CIT  for 5-HTT in the thalamus 
of patients with social anxiety disorder can be interpreted as resulting from a decreased 
extracellular 5-HT concentration near the transporter (allowing 123I-ß-CIT  to bind with higher 
density), from an elevated density of 5-HTT, or from a combination of both. 
Decreased extracellular 5-HT levels in the brain of patients with social anxiety disorder 
would seem to be compatible with the fact that SSRIs are effective in social anxiety disorder 
(Ballenger et al., 1998). In line with this notion, it has been reported that repeated administration 
of SSRIs to healthy volunteers may increase social affiliation (Knutson et al., 1998). More recently, 
Argyropoulos et al. showed that reducing 5-HT availability in the brain through tryptophan 
depletion resulted in a significant increase in challenge-related anxiety in successfully treated 
patients with social anxiety disorder (Argyropoulos et al., 2004). The hypothesis of a decreased 
serotonergic transmission remains in contrast to other reports suggesting that increased 5-HT 
neurotransmission is anxiogenic. Harmer et al. recently reported an impaired recognition 
of fearful facial expression in female volunteers after tryptophan depletion whereas acute 
administration of the SSRI citalopram to healthy volunteers increased the recognition of fearful 
faces (Harmer et al., 2003a; Harmer et al., 2003b). Remarkably, SSRIs often display an acute 
anxiogenic effect that converts into anxiolysis on repeated administration. The mechanism 
responsible for this reversal in effect is unknown, but might be explained by adaptive changes 
(dampening) in the serotonergic system or in other more distal neuronal networks. 
The heightened 5-HTT binding potential may also be the result of increased densities 







serotonergic system (with concomitant lower densities of 5-HT receptors). This possibility would 
be in line with the results from Lanzenberger et al., who found reduced 5-HT1A receptor levels 
in social anxiety disorder (Lanzenberger et al., 2007). Finally, the heightened 5-HTT binding 
potential may also be genetically determined.  Arbelle et al recently reported an association 
between the 5-HTT promoter region 44-base-pair insertion/deletion and shyness in a non-
clinical sample of second-grade children (Arbelle et al., 2003). The investigators reported a 
significant association between the long 5-HTT promoter region 44-base-pair insertion/deletion 
polymorphism and shyness in their sample. Children who were homozygote for the long allele, 
which has been shown to produce higher gene transcription and presumably a higher density 
of the 5-HTT, had significantly higher scores on the Shyness Scales (Murphy et al., 2001).  In so 
far as shyness is an endophenotype for social anxiety disorder, the higher 5-HTT density may 
be interpreted as a risk factor for developing the disorder, which in turn may also explain our 
finding of a heightened 5-HTT binding potential. Unfortunately, the genetics of social anxiety 
disorder have not been adequately studied yet. Interestingly, a study by van Dyck et al. did not 
point at a direct association of higher central 5-HTT levels with the 5-HTT polymorphism but 
suggested a more complex relationship (Van Dyck et al., 2004).
The higher DAT binding potential in the striatum observed in this study is at variance 
with the data reported previously by Tiihonen et al., who found a decreased striatal dopamine 
binding potential in social anxiety disorder by using the same tracer (Tiihonen et al., 1997). 
The difference in outcome between the two studies cannot be readily explained. The most 
obvious differences between the two studies are our more accurate assessment of the VOIs by 
using MRI scan co-registration and the inclusion of psychotropic medication-naïve patients 
without comorbidity in the present study. Both studies, however, had a small number of subjects, 
a limitation that always bears a risk of false-positive outcomes. As discussed above, when 
interpreting the data of our study,  one must consider that the interaction between radiotracer 
and transporter is determined by the amount of radiotracer, the amount of transporter and its 
affinity, and the amount of competing ligands, that is, endogenous dopamine. Thus, the present 
finding can be interpreted as either a lower level of extracellular dopamine or an elevated density 
of DAT in patients with social anxiety disorder or a combination of both.  
By and large, previous studies examining the dopaminergic system in social anxiety 
disorder seem to point to a decreased dopaminergic activity. Schneier et al reported a lower 
123I-iodobenzamide binding potential for the dopamine D2 receptors in patients with social 
anxiety disorder. The authors attributed this finding to a lower dopamine activity (Schneier et al., 
2000). The lower binding potential, however, would also be reconcilable with either an enhanced 
dopaminergic activity or (transitory) high levels of dopamine near the receptors or an altered affinity 
of the receptor as was discussed by Mathew et al. (Mathew et al., 2001). Heightened dopaminergic 
activity may decrease the density or affinity of D2 receptors and simultaneously upregulate the 
density of DAT, whereas high levels of dopamine may compete with 123I-iodobenzamide for 
receptor binding. Data from animal models have shown that a heightened dopaminergic activity 
in the striatum during stress can decrease D2 receptor density (Grant et al., 1998). In line with the 
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notion of an enhanced dopaminergic activity, Barnett et al. recently reported beneficial effects for 
the atypical antipsychotic olanzapine in patients with social anxiety disorder (Barnett et al., 2002). 
Taking together, these findings suggest that our observation of a heightened density of DAT in 
the striatum is probably best explained by an elevated dopaminergic transmission. Interestingly, 
a recent functional MRI study using an implicit learning task as a probe of striatal functioning, 
showed a reduced task-related activation of the striatum in patients with social anxiety disorder 
(Sareen et al., 2007).  Although several studies have implicated the striatum in seasonal affective 
disorder, the involvement of specific striatal subregions has been less thoroughly examined. With 
our exploratory post-hoc analysis we found an increased DAT binding in the right putamen 
in seasonal affective disorder. However, this increase was significant at a level uncorrected for 
multiple comparisons, and the involvement of the putamen in seasonal affective disorder should 
be corroborated in other studies using other methodologies. 
Clearly, the possible role of abnormalities in the dopaminergic and serotonergic systems 
needs to be further elucidated. Both dopamine (through D1 and D2 receptors) and serotonin (through 
5-HT2 receptors) are known to modulate the activity of excitatory (i.e., glutamate) and inhibitory 
(i.e., γ-aminobutyric acid) neurotransmitters in the striatum and related corticothalamolimbic 
circuitry. Data on the exact nature of these interactions are still inconclusive. Finally, based on the 
results of the present study it is not possible to dissect out whether the found dopaminergic and 
serotonergic abnormalities are causal or epiphenomenonal to social anxiety disorder. In our study 
we found no significant correlations between scores on the clinical rating scale and abnormalities 
in the serotonergic and dopaminergic systems.  In general, neuroimaging studies in psychiatry 
tend to find no or only weak correlations between the often heterogeneous symptomatology and 
neuroimaging measures. The previous 123I-ß-CIT  study in social anxiety disorder also did not find 
correlations between binding ratios and symptomatology (Tiihonen et al., 1997).  The absence of 
any correlation in our and the previous study may be due to the psychometric properties of the 
used clinical scale and the heterogeneity of social anxiety disorder as defined by the DSM-IV, but 
can also be interpreted as pointing to the fact that the phenomena of social anxiety disorder are 
not directly related to the found abnormalities. It is also important to note the overlap between the 
binding patterns in patients and controls, suggesting that the found abnormalities may perhaps 
be more related to vulnerability or personality traits. Another explanation may be that the found 
abnormalities are a consequence of having social anxiety disorder (i.e., a ‘scar’ hypothesis).
Our study had several strong points. The patients and controls were pair wise matched. 
Patients were psychotropic medication-naïve and had no comorbid diagnosis on Axis I, and 
most had not received prior psychotherapy. Furthermore, the SPECT data were analyzed using 
coregistered MRI scans, allowing for more precise determination of VOIs. There are some potential 
limitations to the present study.  The sample size was relatively small and we used a limited number 
of VOIs. We visualized binding to the 5-HTT only at four hours after administration of the ligand. 
This time point for visualization, however, could have limited the possibility of finding further 
abnormalities at the level of 5-HTT, as was illustrated by the study of Willeit et al. on seasonal 







of 123I-ß-CIT and also at 24 hours, when a pseudoequilibrium state is reached.  Differences were 
found only in the SPECT acquisitions at 24 hours after the injection.  We followed the method 
described by Kuikka et al. and used paroxetine 20 mg to completely displace the 123I-ß-CIT  from 
5-HTT (Kuikka et al., 1995). Administration of paroxetine could potentially lead to an increase in 
symptoms of (social) anxiety, but such an increase (mild) was reported by only one patient.
Finally, although SPECT is easier to use, is less expensive, and has a higher safety index 
than PET, it also uses semi-quantitative techniques and has a poorer anatomical resolution.
Conclusion
Our data provide direct evidence for the involvement of both the dopaminergic and the serotonergic 
systems in the pathophysiology of social anxiety disorders. These findings needs to be replicated 
and further explored in studies examining the effect of pharmacotherapy and psychotherapy 
on both the serotonergic and the dopaminergic transporter and receptor-binding capacities in 
generalized social anxiety disorder. 
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Mirtazapine in social anxiety disorder:  
a pilot study












Fourteen patients with social anxiety disorder (generalized type), according to DSM-IV criteria, 
were treated with mirtazapine 30 mg for 12 weeks. Twelve patients completed the study. Two 
patients (14.3%) dropped out due to side-effects. Generally, mirtazapine was well tolerated. Five out 
of twelve patients (41.7%) were classified as responders, based on a Clinical Global Improvement 
score of 1 or 2 and a reduction of the Liebowitz Social Anxiety Scale (LSAS) of 40%. The mean 
total score on the LSAS, as well as the anxiety and avoidance subscores, decreased significantly. 
This open pilot study suggests that further investigations are warranted to prove the efficacy of 
mirtazapine in generalized social anxiety disorder.
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Introduction
Social anxiety disorder (SAD), or social phobia, is one of the most common, but still 
underrecognized, psychiatric disorders. The majority of the epidemiological studies found 
lifetime prevalence rates of between 1.7% and 16.1%, using DSM-III, or -IV criteria (Brunello 
et al, 2000). An epidemiological survey found lifetime prevalence rates for the generalized 
type and the specific type of 5.9% and 7.0%, respectively (Stein and Kean, 2000). The essential 
feature of SAD is the fear of being negatively evaluated by others, resulting in avoidance of 
social situations or marked distress. Exposure to the feared situation provokes an immediate 
anxiety response, with symptoms such as trembling, blushing and sweating, and may even take 
the form of a situationally predisposed panic attack. Social anxiety and avoidance interferes 
significantly with the person’s daily routine, social or occupational functioning. Treatment 
options for SAD are cognitive behavioural therapy and drug treatment.
The selective serotonin reuptake inhibitors (SSRIs) are the firstline drug treatment 
for SAD. Other treatment options include monoamine oxidase inhibitors (MAOIs) and 
benzodiazepines (Westenberg, 1999a). Information on other antidepressants, such as 
venlafaxine (Van Vliet et al., 1997; Altamura et al, 1999) and clomipramine (Van Vliet and 
Westenberg, 1999), suggest that they might also be effective in SAD, but data from controlled 
studies are lacking. Mirtazapine is an antidepressant with a novel mechanism of action. It 
has shown to block the α2-adrenergic autoreceptors, resulting in a stimulation of both 
noradrenergic and serotonergic pathways. In addition, mirtazapine also blocks the 5-HT2 and 
5-HT3 receptors. By virtue of its antihistaminergic properties, sedation and weight gain may 
occur (De Boer, 1996). 
Several small open label studies with mirtazapine have been performed in anxiety 
disorders. These studies in anxiety states (Sitsen and Moors, 1994), panic disorder (Carpenter 
et al, 1999), post-traumatic stress disorder (Connor et al, 1999), major depression with 
comorbid generalized anxiety disorder (Goodnick et al, 1999) and major depression with 
anxiety symptoms (Fawcett and Barkin, 1998) suggest mirtazapine has anxiolytic properties. 
The aim of the present study was to assess the possible efficacy of mirtazapine in 




The present study was performed in the outpatient clinic of the University Medical Center Utrecht, 
the Netherlands. Patients meeting DSM-IV criteria for SAD, generalized type, who were aged 18-









Subjects were treated with mirtazapine, 30 mg a day, fixed dose, for 12 weeks. They were evaluated at 
baseline, and at weeks 4 and 12. Responders were treated for another 12 weeks and evaluated at week 
24. None of the patients had used psychotropic medication other than incidental use of oxazepam for 
more than a year prior to the study. Concomitant psychotropic medication was not allowed during the 
course of the study, except for oxazepam 10 mg, with a maximum of 20 mg a day.
The primary outcome measure was the Liebowitz Social Anxiety Scale (LSAS), comprising 
24 items, in which anxiety and avoidance are rated in different social situations on a 0 – 3 points scale. 
The other efficacy measures were the Clinical Global Improvement scale (CGI), and the 
Hamilton Depression Rating Scale (HDRS). The LSAS, and the HDRS were performed at baseline, 
LSAS and CGI were performed at week 4, and the LSAS CGI and HDRS were performed at week 
12. Patients with a reduction of 40% or more on the LSAS total score and a CGI score ‘improved’ (2) 
or ‘much improved’ (1) were considered responders to treatment. Information on side-effects was 
collected by open questioning.
Statistical analysis
Multivariate analysis of variance with repeated measures (ANOVA) was used to evaluate the LSAS 
score in completers. Student’s paired t-test was used to determine significant differences between 
baseline and endpoint on the LSAS and HDRS.
Results
Fourteen patients (11 males and three females), aged 23-44 years, who were suffering from the 
generalized type of SAD, were included in this study. The mean age was 35.5 years. The mean 
Figure 1. The mean Liebowitz Social Anxiety Scale (LSAS) total score of all patients (n=14), divided in an anxiety and 
an avoidance subscore, is shown as percent change from baseline. Statistical analysis revealed a significant change in 
anxiety and in avoidance subscores over time (P<0.005, d.f.=2,12, F=8.85; P<0.001, d.f.=2,12, F=15.13). The changes 
from baseline were already statistically significant as of week 4 (P<0.005, t=4.00; P<0.001, t=7.03). Analysis with last 
observation carried forward also showed a significant change in anxiety and avoidance subscores from baseline to 
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age of onset of SAD was 13.4 years, and the mean duration of illness was 22 years. Previous drug 
treatment with antidepressant medication, mostly SSRIs, was reported in 28.6% of patients. 
Previous cognitive behavioural therapy was applied in 35.7% of the patients, and 64.3% had a 
family history of SAD. Mirtazapine was well tolerated in the majority of the patients. The most 
frequently reported side-effects were sedation and weight gain. Other side-effects reported were 
a dry mouth, muscle cramps, dizziness, insomnia and restless sleep. Two patients used oxazepam 
10 mg occasionally. Two patients dropped out after 4 weeks due to weight gain and sedation. All 
responders to treatment continued taking mirtazapine after completion of the study.
The mean LSAS total score at baseline was 72.6 ± 5.11, and decreased to 48.3 ± 8.18 
at week 12. The change in mean LSAS score is shown in figure 1. Statistical analysis revealed a 
significant change in LSAS score over time (P<0.001, d.f.=2,12, F=12.33), and this was already 
statistically significant by week 4 (P<0.001, t=5.25). Analysis with last observation carried forward 
(LOCF) also showed a significant change in LSAS score from baseline to week 12 (P<0.05, t=3.59). 
Five out of 12 (41.7%) completers were classified as responders to treatment, with a mean LSAS 
total score of 67.6 at baseline (n=5), and 24.5 at week 12. No further improvement was seen at 
week 24. The mean HDRS score decreased from 7.4 at baseline to 5.0 at week 12 (P<0.05;,t=3.62).
Discussion
This open pilot study suggests that mirtazapine is a clinically effective treatment for SAD of 
the generalized type. Mirtazapine was generally well tolerated. Using a stringent criterion for 
response, 41.7% of the patients were classified as responders. Because no comorbidity, such as 
depression, was allowed in this study, these effects of mirtazapine appear to be specific, and 
cannot be attributed to the antidepressant effect of the drug.
The present study is the first study to describe the effects of mirtazapine in SAD. The 
pharmacological properties of mirtazapine are quite different from SSRIs, the treatment of 
choice for SAD thus far. Mirtazapine is an α2-adrenergic receptor antagonist with additional 
antagonistic activity at the 5-HT2 and 5-HT3 receptors. Unlike SSRIs, mirtazapine has no 
direct stimulatory effects on the serotonergic system. According to its different mechanism of 
action, mirtazapine has a side-effect profile that completely differs from SSRIs. Mirtazapine 
is devoid of side-effects common to all SSRIs, such as nausea, sleep disturbances and sexual 
dysfunction, which might influence patient’s compliance and lead to treatment discontinuation 
(Westenberg and Den Boer, 2001). Mirtazapine lacks these side-effects because it blocks the 
5-HT2 and 5-HT3 receptors, and even shows sleep improvement (Thase et al, 2001). In contrast 
to SSRIs, the most prominent side-effects of mirtazapine are daytime sedation and weight gain 
(De Boer, 1996). The efficacy of SSRIs in SAD is well documented.  Studies with SSRIs using 
a similar response criterion as that in the present study, generally show an efficacy of between 
50% and 60%, which is slightly higher than the response of 42% seen in the present study 
(Westenberg, 1999b). However, it should be noted that this was a fixed dose study and that no 







blind research is clearly warranted to confirm the efficacy of mirtazapine in SAD. By virtue of 
its different pharmacological profile, mirtazapine might be an alternative treatment option for 
those patients who can not tolerate, or are unresponsive to SSRIs.
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Elevated alpha-amylase but not cortisol 
















Stress system dysregulation is thought to increase the risk for anxiety disorders. Here we describe 
both hypothalamic pituitary adrenal (HPA) axis and autonomic nervous system (ANS) activity in 
basal non-challenging conditions and after 0.5 mg dexamethasone in generalized social anxiety 
disorder (gSAD) patients. To ensure stress-free sampling we collected saliva and determined 
cortisol and alpha-amylase (sAA), the latter a relative new marker of autonomic activity.
Forty-three untreated gSAD patients without comorbidity were compared with 43 age and 
gender matched controls in non-stressed conditions on sAA and cortisol after awakening, during 
the day (including late evening), and after a low dose (0.5 mg) of dexamethasone. Cortisol and 
sAA were analyzed with mixed models. Additional analyses were done with paired t-tests. Apart 
from the assessments in the morning, gSAD patients had significantly higher diurnal and post-
dexamethasone 16.00h sAA levels. No differences between gSAD and controls in any cortisol 
measurements were found.
In conclusion, in gSAD in basal, non-stimulated conditions and after dexamethasone, we found 
hyperactivity of the ANS, as measured with sAA, but not of the HPA-axis. This suggests a relative 
increased activity of the ANS as compared to the HPA-axis, in line with the observed hyperarousal 
in gSAD.
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Introduction
Social anxiety disorder (SAD; also known as social phobia) is one of the most common anxiety 
disorders (Stein, 2006). It is characterised by the fear of scrutiny by others. In specific SAD (sSAD) 
one or two situations are feared, e.g. speaking in public, while in generalized SAD (gSAD) most 
social situations are involved (American Psychiatric Association, 2000). The anxiety in gSAD 
is often accompanied by hyperarousal, such as increased heart rate, trembling, blushing and 
sweating. These clinical observations suggest an involvement of the stress system (De Kloet et al., 
2005; Goldstein, 2003). However, whether the stress system is involved in gSAD is an unresolved 
question. Moreover, it is unclear under which conditions (basal versus challenge) and which parts 
of the stress system (autonomic nervous system (ANS) or the hypothalamic pituitary adrenal 
(HPA) axis) are involved. In gSAD, these systems have never been studied in concert, instead 
previous studies aimed to elucidate the role of these systems separately.
The function of the HPA-axis in SAD has been investigated by using cortisol levels 
as biological marker. In basal conditions no differences were found between gSAD patients 
and controls with respect to 24-hour urine cortisol levels (Potts et al., 1991; Uhde et al., 1994). 
Moreover, diurnal saliva cortisol levels of adolescent girls with SAD were comparable with those of 
healthy controls (Martel et al., 1999). The last study can be criticized since no distinction was made 
between subtypes of SAD. With some, but not all psychological challenges, HPA-axis dysfunction 
was reported. In one study gSAD patients had a significantly larger cortisol response to the Trier 
Social Stress Test than controls (Condren et al., 2002). Another study found a more outspoken 
dichotomous cortisol response after a stress challenge in gSAD compared to the control group: 
the cortisol responders in the group of gSAD patients had higher cortisol levels after the stress 
task than the cortisol responders in the control group, the cortisol non-responders in the gSAD 
group had lower cortisol levels than the non-responders in the control group (Furlan et al., 2001). 
However, in the study with adolescent girls mentioned above, Martel et al. (Martel et al., 1999) did 
not find any difference in cortisol responses between SAD and controls after a public speaking 
challenge. One study on the effects of a pharmacological challenge with dexamethasone in gSAD 
was published, reporting no differences between gSAD patients and controls in 24-hour urine 
cortisol levels (Uhde et al., 1994).
The function of the ANS has been studied in various ways. Stein and colleagues found 
higher noradrenaline levels in gSAD patients in one study, but could not replicate this finding 
in another (Stein et al., 1992, 1994). One study reported on higher baseline heart rate and blood 
pressure in gSAD patients compared to controls (Bouwer and Stein, 1998), whereas other studies 
did not (Grossman et al., 2001; Laederach-Hofmann et al., 2002; Gerlach et al., 2003).
A major drawback of autonomic measures, especially plasma (nor)adrenaline obtained 
by venipuncture, is the stress accompanying the sampling. Furthermore, heart rate and blood 
pressure are easily influenced by many factors, e.g. posture.
Recently, salivary alpha-amylase (sAA) has been proposed to reflect ANS activity 







activity shows a diurnal profile with a decrease during the first 60 minutes after awakening and an 
increase during the rest of the day (Rohleder et al.,  2004; Nater et al., 2007). sAA levels were relatively 
independent of several possible confounders like gender, body mass index (BMI), activity level, 
smoking, eating and drinking but significantly associated with chronic stress and stress reactivity in 
healthy volunteers (Nater et al., 2007).
Psychological and  physiological challenges were followed by increases in sAA (Gilman 
et al., 1979; Bosch et al., 1996; Chatterton, Jr. et al., 1996; Chatterton, Jr et al., 1997; Rohleder et 
al., 2004; Rohleder et al., 2006; Nater et al., 2005; Nater et al., 2006; Kivlighan and Granger, 2006), 
although most studies failed to find significant correlations between adrenaline and noradrenaline, 
peripheral markers of the ANS, and sAA (Rohleder et al., 2004; Nater et al., 2006) indicating that 
stress-dependent sAA increases reflect changes of the ANS in general, not catecholamine increases. 
Furthermore, two pharmacological challenges provided direct evidence that sAA measures ANS 
activity. Propranolol (a non-selective bèta-blocker), combined with a stressful task, resulted in 
lowering of sAA, showing the sensitivity of sAA to changes in adrenergic activity (Van Stegeren et 
al., 2006). Similarly, a yohimbine (an α2-receptor antagonist) challenge induced not only increases of 
peripheral noradrenaline levels but also increases of sAA levels compared to placebo. No correlations 
were found between adrenaline, noradrenaline and sAA, indicating that sAA reflects central 
noradrenaline release in stead of peripheral noradrenaline secretion (Ehlert et al., 2006). More 
research on sAA is discussed in the review of Granger et al. (2007).
The question remains whether there is a difference in basal autonomic activity in gSAD as 
compared to controls. Furthermore, we aimed to investigate the ANS and the HPA-axis in concert, 
since the specific balance between these stress systems, as was shown in experimental animal research, 
is often overlooked (Goldstein, 2003). Considering sAA as a measure of autonomic activity together 
with stress-free sampling of saliva stimulated us to use sAA to test basal autonomic activity in gSAD.
Here we report the awakening and diurnal rhythm of both cortisol and sAA, in basal 
conditions. In order to also measure the feedback sensitivity of the HPA-axis, we added a low-dose 
dexamethasone suppression test with 0.5 mg (Gaab et al., 2002), which is more sensitive to detect 
differences between different groups than higher dosages. We expected, based on former research, not 
to find differences in HPA-axis function in gSAD as compared to controls. However, we hypothesized 
that the ANS, as measured using sAA, would show hyperactivity in gSAD during the day.
Methods
Subjects
Forty-three patients with gSAD and 43 age (± 5 years) and gender matched healthy controls 
participated in this study. No life-time psychiatric comorbidity or clinically significant medical 
disorders, such as endocrinological disorders, were allowed. Patients were not currently treated for 
gSAD. Subjects were excluded in the case of alcohol consumption of over three units a day, using drugs 
of abuse or smoking more than 20 cigarettes a day. Use of psychotropic medication (including bèta-
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blocking agents) had to be stopped at least 14 days before the trial, with the exception of oxazepam 
(half life 4 to 15 hours) with a maximum dosage of 30 mg a day and only when used sporadically 
on an ‘as needed’ basis. It was allowed to be used up to 24 hours before the test days. No oral 
glucocorticoids were allowed in 6 months prior to the study. Because of the influence of estradiol 
on the HPA-axis, women were tested during the follicular phase of the menstrual cycle and women 
using oral contraceptives in the stop week. Women were asked about their menstruations in order 
to assess perimenopause (period of irregular menstruations before menopause) or menopause 
(last menstruation over a year ago). In case of any doubt, hormonal assessments were performed 
and discussed with a gynaecologist. Perimenopausal women were excluded, postmenopausal 
women were included. 
Procedures
The protocol was conducted in accordance with the declaration of Helsinki and approved by 
the Medical Ethical Committee of the Leiden University Medical Center. Patients and controls 
were recruited by advertisements and interviews in local papers. Subjects contacted us and the 
investigator screened them by telephone on in- and exclusion criteria. If the criteria were met, the 
possible subjects were invited to visit our hospital. The possible controls were invited for a screening 
visit and received an information letter regarding the study by mail. In the case of suspected gSAD, 
patients were first invited for a diagnostic interview, then received the information letter and when 
eligible they were invited for the screening visit. Screening was performed within a 2-week period 
prior to the study. Before starting the screening, after complete description of the study, subjects 
signed the informed consent form. At the screening visit, DSM-IV diagnosis was confirmed and 
comorbidity was checked with the MINI Plus 5.0.0 (Van Vliet and De Beurs, 2007). Subjects were 
asked for their medical history and physical symptoms of illness. Then a physical examination was 
done, and on indication a laboratory investigation. The Liebowitz Social Anxiety Scale (LSAS) 
and the 17-points Hamilton Rating Scale for Depression (HRDS) were used in both groups to 
measure symptom severity (Liebowitz, 1987; Hamilton, 1960). Subjects with a HRDS score over 16 
were excluded. A summary of the Structured Trauma Interview was used to make an inventory of 
experienced traumatic events (Draijer, 1989), because trauma might influence the HPA-axis even 
in people without PTSD.
In- and exclusion criteria were checked. After planning the two test days, salivettes and 
practical instructions were given.
The saliva samples were collected by the subjects at home during two non-working days. 
Patients and controls were specifically requested not to expose themselves to social situations or 
strenuous exercise during the test days, in order to measure stress markers in a basal, non-stressed 
condition. On test day I, samples were taken immediately after awakening, 30 minutes, 45 minutes 
and 60 minutes after awakening, at 1100 h, 1500 h, 1900 h, and 2200 h. At 2300 h they ingested a 
tablet of 0.5 mg dexamethasone. On test day II (the following day) subjects were asked to collect 
saliva samples at 900 h and 1600 h. After these test days subjects returned the salivettes through 







We measured the presence of dexamethasone in saliva in order to check on the reliability 
of the dexamethasone suppression test (DST) and to have an impression of the compliance of the 
subjects in both groups.
Instructions for saliva sampling
Saliva was obtained using salivette collecting devices, containing a cotton wad (Sarstedt, 
Rommelsdorf, Germany). For each sample subjects were asked to chew on this wad until the 
cotton was saturated with saliva, to put it back into the tube and then to keep it in the refrigerator. 
In order to improve compliance and to detect deviations from the protocol subjects were told: (1) 
to strictly follow the procedures and the time schedule for saliva sampling to obtain valuable data; 
(2) to record sample times and activities in the hour before sampling; (3) that we would be able 
to check compliance by looking at their cortisol curves.  For the awakening sample, subjects were 
instructed to start saliva sampling immediately at awakening. Subjects were told to complete the 
early morning samples (awakening and 30 minutes, 45 minutes and 60 minutes afterwards) before 
brushing their teeth and having breakfast to avoid contamination of saliva with blood, food or 
drinks. They also were requested not to eat fruit or drink fruit juices and to thoroughly rinse their 
mouth with tap water before sampling saliva to avoid contamination.
Laboratory analysis of sAA and cortisol
The determination of cortisol in saliva was performed with a competitive electrochemiluminiscence 
immunoassay ECLIA using a Modular Analytics E1 70 immunoassay analyzer from Roche 
Diagnostics (Mannheim, Germany). The sample volume was 20 µL. The detection limit was 2 
nmol/l (Van Aken et al., 2003).
The determination of sAA was performed with an enzymatic colorimetric assay using the 
maltoheptaoside (EPS) substrate on a P-module clinical chemistry analyzer (Roche, Mannheim, 
Germany) in 400-fold diluted saliva samples. The detection limit was 3 U/l (Lorentz, 1998).
The dexamethasone concentration was measured by a home-made radioimmunoassay 
(Department of Clinical Chemistry, Leiden University Medical Center, J. van Pelt). Dexamethasone 
was extracted from saliva and then analyzed by radioimmunoassay, which was performed with 
the antidexamethasone antibody from IgG Corporation (Nashville, Tennessee). The protocol from 
IgG Corporation was slightly modified. The lower limit of detection was 50 pmol/l (17.5 ng/l) and 
the reported cross-reactivity for cortisol is 0.04% (Weijtens et al., 1997).
Statistics
Outliers in cortisol levels were removed when they were above 50 nmol/l and higher than the mean 
+ 3 S.D. Outliers in sAA levels were removed when they were above the mean + 3 S.D. The missing 
data were interpolated linearly. This was not possible for missing data on time points 1, 8, 9, or 
10, because they were at the end or beginning of the day. Missing data on time point 1 and 8 were 
replaced by those of time point 2 and 7, respectively. Missing data on time point 9 and 10 the data 
were recorded as missing.
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1. For evaluation of cortisol and sAA levels, Area Under the Curve with respect to ground 
(AUCg) values were first calculated for each subject separately and relative to the baseline value, 
for both the awakening cycle as well as for diurnal cortisol (11-22 h).  We used the following 
formula for the calculation of the AUCg awakening : (((valuet1 + value t2) / 2) x (t2-t1)) +  (((value t2 
+ valuet3) / 2) x (t3-t2)) + (((valuet3 + valuet4) / 2) x (t4-t3)); and the corresponding formula for the 
diurnal AUCg: (((valuet5 + value t6) / 2) x (t6-t5)) + (((valuet6 + valuet7) / 2) x (t7-t6)) + (((valuet7 + 
value t8) / 2) x (t8-t7)).
Subsequently, the thus summarized data were evaluated via mixed modeling, in order to 
take the paired nature of the data within matched pairs into account. The model is formulated as
1 1( ) ( )...ij i ij ij k k ij ijY X CF CFα β γ γ ξ= + + + + +
 
where ijY  are the modeled responses on the observed 
pairs, with i=1,…,43 indicating the pair and j=1,2 denoting the case and control status respectively 
of each of two observations within each ith pair. We define ijX =1 for j=2 and zero otherwise, 
such that β  denotes the effect of substantive interest, contrasting cases from controls. The term 
1 1( ) ( )...ij k k ijCF CFγ γ+ +  corrects for observed confounder effects, with 1, ..., kCF CF  a set of k 
confounders. To obtain an analysis comparing cases with controls within pairs, we need to adjust 
for between-pairs heterogeneity, through assumption of the random effect 
2(0, )i N αα σ≈ . Conditional 
on both the between-pairs random effect and observed confounder adjustments, outcomes are 
assumed exchangeable with this model through assumption of residual normal error. We refer to 
Verbeke and Molenberghs (2001) for further details on the model.
For the cortisol data the mixed models were corrected for month of measurements 
(dark months: October through February; light months: March through September), time of 
awakening, and smoking (number of cigarettes a day), as was derived from yet unpublished 
data of our own center on determinants of salivary cortisol in 494 healthy controls. For the 
sAA data the mixed models were corrected for the use of coffee, smoking and the Body Mass 
Index as was based on the review of Granger et al. (2007). The evaluation of cortisol levels in the 
evening and sAA and cortisol levels subsequent to dexamethasone intake was based on separate 
analyses of the measurements taken at test day I at 2200 h and at test day II at 900 h and 1600 h, 
using the above described mixed model approach. For this statistical model, the assumption is 
that the residuals are normally distributed after the incorporation of the confounding factors in 
the model. Here, the residuals of both the sAA and the cortisol data were skewed. Therefore we 
performed a square root transformation for the sAA data, and for cortisol a log transformation, 
after which the residuals were investigated anew and found to be of normal distribution.
2. Separate analyses were implemented for patients and controls to investigate the 
presence of a cortisol awakening rise (CAR). Paired t-tests (two-sided) were carried out for 
cortisol measurements at 30 minutes post-awakening relative to the awakening measurements. 
These data were normally distributed.
3. All mixed model analyses were carried out through the SPSS 14.0 mixed model 
routine. 
We are purposely presenting both the raw, unadjusted p-values as reported by the analyses and 









Initially 46 patients and 54 controls were screened for this study. Three patients and eleven controls 
dropped out. For more detailed information on this see the flow chart in Figure 1. Forty-three 
patients with gSAD and 43 age (± 5 years) and gender matched healthy controls participated in this 
study. Subject characteristics are given in Table 1. The gSAD group was assessed within 13 months, 
the control subjects within 2.5 years.
Of the 43 patients and controls, some data were missing due to insufficient saliva collection. 
For all missing data, the matching data from the other group were removed from the analyses as 
well. Insufficient saliva was collected for cortisol measurement of test day II at 900 h in three subjects 
(n=40), and of cortisol test day II at 1600 h in one subject (n=42). Insufficient saliva was collected 
for sAA measurements of the AUC awakening in one subject (n=42) and at test day II 900 h in one 
subject (n=42). After the test days it appeared that one patient used a bèta-blocker for high blood 
pressure, but did not mention this before. The data of this patient were included in the analyses.
N=279 
n=279 




Not suitable (n=39): 
• 19 patients had (a history of) comorbidity  
• 6 patients met an exclusion criterion  
• 14 patients were not interested  
Drop-outs (n=3): 
•  1 patient did not show 
•  In 1 patient diabetes mellitus was       
discovered 









Not included (n=11): 
•  1 subject returned mouldy samples  
•  6 subjects had a (history of a) 
psychiatric disorder  
•  4 subjects were no match  
Figure 1. Flow chart of recruitment and inclusion process of gSAD patients and controls. The numbers of patients 
and controls that entered the various stages of the recruitment and inclusion process.
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Salivary cortisol
At test day I, we found no differences between gSAD patients and controls on the AUC cortisol 
after awakening as analyzed with mixed models and corrected for the confounders (p=0.864) 
(see Figure 2 and Table 2). In each group we compared cortisol levels at 30 minutes after 
awakening with cortisol levels directly at awakening with a paired sample t-test. In both the 
gSAD and control group no significant differences were found between these time points (mean 
= -2.62, S.D. = 9.23, p = 0.07; mean = -0.035, S.D. = 5.56, p = 0.967), reflecting the absence of a 
CAR in both groups (see Figure 2).
Mixed models analysis with correction for confounders also showed no differences 
between both groups in the AUC diurnal cortisol and the cortisol level at 2200 h (p=0.773; 
p=0.201) (see Figure 2 and Table 2).
Compliance was checked in both groups. Dexamethasone was present in the saliva at 
day II of all subjects, except for three controls and one patient. Since an obvious suppression 
of their cortisol levels was found, they probably did ingest the dexamethasone. At test day II 
post-dexamethasone cortisol levels (900 h and 1600 h) did not differentiate between the groups 
(p=0.920; p=0.256) (see Table 2 and Figure 2).
Taken together, we did not observe significant differences in saliva cortisol at any 
measure of the HPA-axis we used.
gSAD patients (n=43) Healthy controls (n=43)
CHARACTERISTICS
Number of women / men 21 / 22 21 / 22
Age women / men (years) 42.1 (± 11.8) / 41.3 (± 13.9) 41.7 (± 12.2) / 41.4 (± 14.5)
Age total (years) 41.7 (± 12.8) 41.6 (± 13.3)
Smoking 16.3% (n=7) 14.0% (n=6)
Number cigarettes/day 8.6 (± 6.3) 10.3 (± 5.7)
Use of alcohol 86.0% (n=37) 74.4% (n=32)
Number of units alcohol/week 6.6 (± 4.2) 5.7 (± 3.7)
BMI 23.9 (± 3.4) 24.4 (± 3.9)
LSAS score 78.2 (± 19.6) 8.6 (± 5.6)
HRDS score 5.7 (± 3.1) 1.3 (± 1.5)
Trauma 49% (n=21) 40% (n=17)
MEDICATION
Beta-blockers 2% (n=1) 0%
Oxazepam 10 mg (as needed) 2% (n=1) 2% (n=1)
Nasal glucocorticoids 2% (n=1) 0%
Inhaled glucocorticoids 2% (n=1) 2% (n=1)
Glucocorticoid crème 0% 5% (n=2)
Oral contraceptives 19% of women (n=4) 38% of women (n=8)
gSAD=generalized social anxiety disorder; BMI=body mass index; LSAS=Liebowitz Social Anxiety Scale; 
HRDS=Hamilton Rating Scale for Depression








In contrast, sAA did show statistically significant differences between patients and controls as 
analyzed with mixed models, after correction for the confounding factors. On test day I in the 
morning, during the first hour after awakening, we did not find significant differences in the 
AUC sAA awakening (p=0.114) (see Figure 3 and Table 2). However, during the day (from 1100 
h to 2200 h), the AUC sAA diurnal was much higher in gSAD patients as compared to controls 
(p=0.022).  At 1500 h sAA levels were almost twice as high in patients as compared to controls. For 
details see Figure 3 and Table 2.
On test day II, post-dexamethasone sAA levels were significantly higher in gSAD patients 
compared to controls at 1600 h (p=0.02) (see Table 2, and Figure 3), but not at 900 h (p=0.059) (see 
Table 2 and Figure 3). In Table 2 also the Bonferroni corrected p-values are given.
Table 2 Cortisol (log transformed) and sAA (sqrt transformed) data in gSAD patients and controls 
as analyzed with mixed models (within matched pairs)
Mean gSAD Co F p p (bonf. corr.) n
Cortisol (nmol/l)
Day I AUC awakening 962.2 1060.9 0.030 0.864 - 43
AUC diurnal 4993.6 5486.5 0.084 0.773 - 43
Late evening (2200 h) 3.5 4.5 1.687 0.201 - 43
Day II Post-dex. 900 h 4.1 4.5 0.010 0.920 - 40
Post-dex. 1600 h 3.384 3.029 1.307 0.256 - 42
Amylase (U/ml)
Day I AUC awakening 9299.145 6959.123 2.612 0.114 - 42
AUC diurnal 225147.69 146808.58 5.413 0.022* 0.044* 43
Day II Post-dex. 900 h 191.776 130.758 3.794 0.059 - 42
Post-dex. 1600 h 327.542 206.047 5.628 0.020* 0.040* 43
sAA=salivary alpha-amylase; gSAD=generalized social anxiety disorder; Co=controls; AUC awakening = the area 
under the curve of cortisol levels at awakening, 30 minutes, 45 minutes and 60 minutes after awakening; AUC di-
urnal= the area under the curve of cortisol levels at 1100 h, 1500 h, 1900 h and 2200 h. Late evening cortisol is the 
cortisol level at 2200 h. Post-dex. are the data following the ingestion of 0.5 mg dexamethasone. These data reflect 
mixed models analysis of the cortisol and sAA data, corrected for confounders. The cortisol data were log-transfor-
med. For the sAA data a square root transformation was performed. The F and p-values reflect analyses with the 
transformed data. P (bonf. corr.) reflects the bonferroni corrected significant p-values. * means that the data were 
statistically significant. For cortisol the confounders that were taken into account were month of measurements, time 
of awakening, and smoking, for sAA the confounders that were taken into account were use of coffee, smoking, and 
the Body Mass Index.
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Discussion
Here we show that gSAD patients differ from healthy controls in their diurnal sAA and post-
dexamethasone sAA level at 1600 h, but not in their cortisol levels. This suggests an imbalance 
between the two branches of the stress system. Several arguments indicate that the increased diurnal 
sAA levels really indicate higher ANS activity in gSAD. However, as discussed in the introduction, 
previous studies in gSAD with traditional markers of ANS activity like (nor)adrenaline, heart rate 
and blood pressure were contradictory. First this could be explained by the findings that sAA as 
a marker for the ANS is relatively independent from several possible confounding factors as was 
reported before (Nater et al., 2007), while (nor)adrenaline levels, heart rate and blood pressure, are 
easily influenced by many factors, including posture and venipuncture. Second, we assessed sAA 
several times a day contrary to the single or closely clustered assessments of the ‘classical’ parameters.
The diurnal sAA levels and patterns we describe here were very similar to the sAA curves 
that were found before (Rohleder et al., 2004; Nater et al., 2007), indicating the validity of our 
results.  Although it was not the aim of our study, we found no effects of dexamethasone on sAA. This 
means that the post-dexamethasone ANS hyperactivity we found in gSAD probably also reflects basal 
hyperactivity as we found on test day I.
Mean gSAD Co F p p (bonf. corr.) n
Cortisol (nmol/l)
Day I AUC awakening 962.2 1060.9 0.030 0.864 - 43
AUC diurnal 4993.6 5486.5 0.084 0.773 - 43
Late evening (2200 h) 3.5 4.5 1.687 0.201 - 43
Day II Post-dex. 900 h 4.1 4.5 0.010 0.920 - 40
Post-dex. 1600 h 3.384 3.029 1.307 0.256 - 42
Amylase (U/ml)
Day I AUC awakening 9299.145 6959.123 2.612 0.114 - 42
AUC diurnal 225147.69 146808.58 5.413 0.022* 0.044* 43
Day II Post-dex. 900 h 191.776 130.758 3.794 0.059 - 42
Post-dex. 1600 h 327.542 206.047 5.628 0.020* 0.040* 43
Figure 2. Awakening, diurnal and post-dexamethasone salivary cortisol levels (± S.E.M.) in gSAD patients and con-
trols. Awak. = awakening samples, they were taken at the moment of awakening, and after 30 minutes, 45 minutes 
and 1 hour after awakening at test day I. The diurnal samples were taken at 1100 h, 1500 h, 1900 h and 2200 h at test 
day I. Post-dexamethasone salivary cortisol levels: 900 h and 1600 h are the time points at test day II, the day fol-







With respect to cortisol levels we did not find differences between gSAD patients and 
healthy controls, as was previously shown by others (Potts et al., 1991; Uhde et al., 1994; Martel et 
al., 1999).
In contrast to what might be expected, neither in the gSAD patients nor in the controls a 
cortisol awakening rise (CAR) was found. This may be the consequence of asking the participants to 
sample saliva cortisol during rest days. It has been reported that the CAR is smaller in weekend days 
as opposed to working days (Kunz-Ebrecht et al., 2004). It also might be the effect of non-adherence 
to the protocol (Thorn et al., 2006), the effect of the time of awakening, which apparently is different 
in weekend days (Clow et al., 2004), or the effect of the great variation of cortisol levels in the general 
population.
No statistically significant differences between the groups were observed in the DST, 
with both groups showing suppression of cortisol. HPA-axis suppression in the gSAD group was 
comparable to those in healthy controls being in line with a previous report (Uhde et al., 1994). 
Thus it could be concluded from the present study that in basal conditions the HPA-axis function is 
Figure 3. Awakening, diurnal and post-dexamethasone salivary alpha-amylase levels (± S.E.M.) in gSAD patients 
and controls. Awak. = awakening samples, they were taken at the moment of awakening, and after 30 minutes, 45 
minutes and 1 hour after awakening at test day I. The diurnal samples were taken at 1100 h, 1500 h, 1900 h and 2200 
h at test day I. Post-dexamethasone salivary alpha-amylase levels: 900 h and 1600 h are the time points at test day II, 
the day following the ingestion of dexamethasone.
* means a statistical difference between patients and controls in sAA levels as analyzed with mixed models (p=0.009).
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normal, whereas there is an increased activity of the autonomic system itself.
We were the first to investigate the HPA-axis and the ANS together in basal non-stimulated 
conditions in gSAD, and had the opportunity to directly compare these two systems in the same 
group of patients and controls. Other strenghts of the study are that we used a relatively large group 
of patients with individually matched controls. The patients were suffering from pure gSAD, no life-
time comorbidity was allowed. For cortisol we tried to prevent the influence of confounding factors 
in several ways. Patients and controls were matched for age and gender. Subjects that were heavy 
smokers or drinkers were excluded. Furthermore, we corrected for several remaining confounding 
factors in the statistical analyses. For sAA we also took several possible confounders into account, 
based on the review of Granger et al. (Granger et al., 2007). Another strength is that cortisol and 
sAA were measured in saliva (Gozansky et al., 2005; Rohleder et al., 2006), which has the advantage 
of non-stressful sampling as opposed to measurements in blood. In addition, saliva samples were 
collected at home, on non-working and non-stressful days, without engaging in social situations. 
This approach secures equal conditions in both groups, without confounding factors as anticipatory 
and social anxiety in the gSAD group. 
In asking participants to sample saliva at home we optimized the chances that assessments 
took place under basal conditions. In doing so we followed many other studies (Clow et al., 2004). 
However, unsupervised sampling at home may decrease compliance. We took several measures to 
control for this possibility. First, we stimulated compliance by asking the participants to write down 
the time of sampling and the activities they did the hour before sampling, and by informing them 
about our plans to check compliance, as it has been demonstrated that such a procedure enhances 
compliance (Kudielka et al., 2003). Second, we checked saliva dexamethasone levels and found no 
indications of non-compliance in any of the participants. Nevertheless, we cannot rule out that non-
compliance to the protocol influenced our data on cortisol as well as sAA. Hence, we might have 
missed existing differences between gSAD patients and controls at the cortisol and sAA awakening 
responses. Furthermore, our data might have been of more value if we had measured full awakening 
responses of both markers after the DST.
In conclusion, under basal conditions we found no changes in HPA-axis activity but, in 
contrast, an increased autonomic activity. This suggests an imbalance in the stress-system probably 
by relative increased activity of the autonomic system as compared to the HPA-axis.  These findings 
are in line with the hyperarousal observed in gSAD patients, as it might perhaps be the result of 
the hyperactivity of the ANS. Alternatively, the hyperactivity of the ANS might be the result of the 
chronic stress accompanying the continuing fear to be humiliated by others.  Further research could 
be directed at the associations between hyperarousal and sAA in gSAD and at differences in ANS 
activity between gSAD and other anxiety disorders.
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Tryptophan depletion affects the autonomic 


















In generalized social anxiety disorder (gSAD), serotonergic dysfunctions are found, as well 
as abnormalities of the autonomic nervous system (ANS) in basal conditions and of the 
hypothalamic pituitary adrenal (HPA) axis in response to psychological challenges. These findings 
raise the question whether these phenomena are interrelated. Therefore we designed a study in 
which two groups with nine pair wise age and gender matched gSAD patients (total of 10 men 
and 8 women), who were successfully treated with a selective serotonin reuptake inhibitor (SSRI), 
underwent a tryptophan depletion challenge (TD) or a placebo condition. A TD procedure 
temporarily decreases serotonergic neurotransmission. In order to activate the stress system the 
TD/placebo challenge was combined with a public speaking task. We assessed ANS responses, as 
measured with the promising new marker salivary alpha-amylase (sAA), and HPA-axis responses, 
as measured with salivary cortisol. The most important result was that the TD group showed a 
significant larger sAA response to the public speaking task as compared to the placebo group, 
reflecting hyperresponsivity of the ANS in this group, whereas no differences were seen in cortisol 
responses. This suggests that in gSAD there is a vulnerability of the ANS more than the HPA-axis.
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Introduction
Several biological systems behave differently in generalized social anxiety disorder (gSAD). With 
respect to the serotonergic system higher binding potentials for the serotonin transporter in the 
thalamus and reduced 5-HT1A receptors levels have been found (see among others (Van Der Wee 
et al., 2008). In addition, challenges with various serotonergic agonists and tryptophan depletion 
induced exaggerated responses (see among others (Van Veen et al., 2007). Besides, the favorable 
effects of selective serotonin reuptake inhibitors (SSRIs) in gSAD suggest serotonergic involvement 
(Blanco et al., 2003). A reciprocal interaction between the central serotonergic and noradrenergic 
systems has been proposed (Tassin, 2008), suggesting that SSRIs could also modulate autonomic 
function.
The autonomic nervous system (ANS) and the Hypothalamic Pituitary Adrenal-axis 
(HPA-axis) behave also different in gSAD. In basal, non-stressed conditions, diurnal hyperactivation 
of the ANS was found, as measured with the promising new marker salivary alpha-amylase (sAA) 
(Van Veen et al., 2008). During psychological stress the increase in systolic blood pressure and 
heart rate was larger than in normal controls (see among others Gerlach et al., 2003). With respect 
to the HPA-axis in basal conditions no change was found (Van Veen et al., 2008), but psychological 
stress induced hyperfunction (see among others (Condren et al.,  2002).
Taken together, this research leads to the question whether the serotonergic system, 
ANS and HPA-axis are interrelated in gSAD, and, more specifically, whether manipulation of the 
serotonergic system with, for example, SSRIs leads to alterations in ANS and HPA-axis function.
In this paper we report about the effects of a tryptophan depletion (TD) challenge 
compared to placebo on ANS and HPA-axis responses to public speaking stress in SSRI-treated 
gSAD patients. Acute TD is a procedure that temporarily decreases serotonergic neurotransmission, 
decreasing the efficacy of SSRIs (Hood et al., 2005). The stress system was activated by means of a 
public speaking challenge. Anticipatory anxiety and learning were avoided by dividing the gSAD 
patients in two groups, instead of using a crossover design. The neuroendocrine parameters sAA, 
as a marker of the ANS, and cortisol, as a marker of the HPA-axis, were measured. Based on 
our findings in basal conditions (Van Veen et al., 2008) we expected to find the ANS to be more 
sensitive to stress than the HPA-axis.
Methods
Subjects
Eighteen patients with gSAD (10 men, 8 women), pair wise matched on age and gender, were 
randomly assigned to two conditions, TD and placebo. They were responders to 20 weeks of 
treatment with citalopram 20-60 mg a day. No life-time psychiatric comorbidity (confirmed with 







as endocrinological disorders, were allowed. Before the test day the Liebowitz Social Anxiety Scale 
(see also Van Veen et al., 2008) and the Beck Depression Inventory (BDI) were used to measure 
symptom severity (Beck and Steer, 1987).
In case of heavy smoking, abuse of alcohol, or use of drugs of abuse subjects were 
excluded. Use of psychotropic medication (including beta-blocking agents) had to be stopped at 
least 14 days before the trial. Women were tested during the follicular phase of the menstrual cycle 
and women using oral contraceptives in the stop week. Perimenopausal women were excluded, 
postmenopausal women were included. 
Procedures
The protocol was approved by the Medical Ethical Committee of the Leiden University Medical 
Center. The study was carried out in accordance with the Declaration of Helsinki. All procedures 
were conducted with the adequate understanding and written informed consent of the subjects. 
At the test day an indwelling catheter was placed in an antecubital vein. At 1000h the 
TD amino-acid mixture or placebo was ingested. At 1525h patients received instructions for the 
public speaking task. At 1600h the public speaking task started, and ended at 1610h. The test day 
ended at 1700h.
For the TD patients fasted overnight and were kept on a low protein diet during the test 
day until the following morning. The TD amino-acid drinks we used were the standard 100 mg 
drink (see Hood et al., 2005).  During the test day, LNAAs, total TRP and 5-hydroxy-trypthophan 
(5-HTP) were assessed. The public speaking test was based on the principles of the Trier Social 
Stress Test (Kirschbaum et al., 1993), but slightly modified. Patients were given 15 minutes to 
prepare a 10 minute speech on a subject of choice. It was suggested (but not the case) that they 
were judged by an audience behind the one-way mirror-wall and that the whole session would be 
video-taped.
During the test day, plasma was obtained, behavioural measurements such as the Visual 
Analogue Scale (VAS) Anxiety and a short version of the Profile of Mood States (POMS) (Wald 
and Mellenbergh, 1990), and physiological assessments, such as heart rate and tension (Dinamap® 
Pro 100), were done at baseline (t0), after the TD (t1), after the preparation for the public 
speaking challenge (t2), and after the public speaking challenge (t3). Saliva for cortisol and sAA 
measurements was first collected after the TD and thereafter at 12 time points until 7 hours after 
the public speaking challenge.
Neuroendocrine assessments
TRP, TRP/LNAA  and 5-HTP
Plasma total TRP, the LNAAs phenylalanine, tyrosine, TRP, isoleucine, leucine and valine, 
and 5-HTP were assessed to evaluate the efficacy of the TD procedure. For the amino acids, 
quantitative amino-acid analysis was performed by high-performance liquid chromatography as 
described elsewhere (Fekkes et al., 1995). The ratio total TRP / LNAA was calculated as 100 times 
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the concentration of TRP divided by the summed concentrations of the other LNAAs. For the 
5-HTP assay, see (Gijsman et al., 2002). The lower limits of detection and quantification were 0.5 
and 1.7 ng/ml, respectively. The coefficients of variability for precision and reliability were 2.6% 
and 7.9%, respectively (Gijsman et al., 2002).
sAA and cortisol 
The determination of sAA and cortisol was described in our previous study (Van Veen et 
al., 2008).
Statistics
Since the subjects were pair wise matched, the TD and placebo group were compared with 
paired-samples t-tests.
1.  For baseline characteristics, the groups were compared on age, severity of gSAD symptoms 
after treatment (LSAS score), depressive symptomatology (BDI score), smoking, the use of 
alcohol and dosage of citalopram.
2.  The effects of the TD alone (after the TD and before the public speaking challenge) on sAAt1, 
cortisol t1, VAS anxietyΔt1-t0, POMS Δt1-t0, heart rate Δt1-t0, and systolicΔt1-t0 and diastolicΔt1-t0 blood 
pressure were analyzed. 
3.  The neuroendocrine data in response to the public speaking test were normalized by dividing 
all sAA and cortisol values by the first value (t1), which was obtained before the public speaking 
challenge. The normalized data show the relative increase in sAA and cortisol in response to 
the public speaking challenge. We normalized the data because of the small sample sizes, large 
variations between subjects in individual sAA levels, and to take into account the possible 
influences of the TD/placebo condition on the neuroendocrine data before the start of the 
public speaking challenge. 
4.  The TD and placebo group were compared on relative sAA and cortisol levels after the public 
speaking challenge (t3). Also the VAS anxietyΔt3-t1, POMS Δt3-t1, heart rate Δt3-t1, systolic Δt3-t1 and 
diastolic Δt3-t1 blood pressure at this time point were analyzed. 
All analyses were done with SPSS 16.0.
Results
Subjects
The TD and placebo group showed no significant differences on age (p=0.74; mean of both groups 
together 39.1), symptom severity (p=0.15; mean LSAS score 28.6), use of alcohol (p=0.67; mean 4 
units a week), smoking (p=0.2; mean 1.1 cigarette a day) and the dosage of citalopram (p=0.35; mean 
42.4 mg a day). One patient stopped just after the explanation of the public speaking task, because 
of acute panic. The data that were already collected were included in the analyses. Unfortunately, it 







was included in the analyses.
Tryptophan depletion
The TD procedure resulted in a reduction at t1 of total TRP of 90.6%, of the TRP/LNAA ratio of 
96.6%, and of 5-HTP of 80.2%. The placebo drink resulted in an increase in total TRP of 84.3%, a 
decrease of the TRP/LNAA ratio of 46.3%, and an increase of 5-HTP of 12.6%. 
Figure 1. The relative (normalized data) sAA and cortisol responses (± S.E.M.) before and after the public speaking 
challenge. The p-value is the result of the comparison of the relative increases at t3 between the TD and placebo group 
by means of a paired-samples t-test: t1 is after the TD challenge and before the public speaking challenge; t2 is after 
the preparation phase and before the public speaking challenge; t3 is after the public speaking challenge.
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Neuroendocrine assessments
The effects of the TD/placebo condition alone on sAA and cortisol (t1) revealed no statistical 
differences (p = 0.124, p = 0.394).  However, significant increases in the relative sAA reponses to 
the public speaking task (t3) were seen in the TD group compared to placebo (p=0.013; bonferroni 
corrected p-value = 0.026). No significant differences were seen in relative cortisol increases 
(p=0.95). For details see Figure 1 and Table 1.
Behavioural and physiological assessments
No statistical significant differences were found in heart rate, blood pressure, and anxiety and 
mood assessments between the TD and the placebo condition. 
Discussion
The most important finding of this study is that in successfully SSRI-treated gSAD patients sAA 
responses to a social stress test were significantly higher in the TD condition as compared to 
placebo. No differences were found in salivary cortisol, as well as anxiety, mood, blood pressure 
and heart rate responses. The TD condition without public speaking did not differ from the placebo 
condition in sAA, cortisol, anxiety, depressive symptoms, blood pressure and heart rate. 
The higher sAA response to stress in the TD group was not accompanied by higher 
responses of the more traditional markers of autonomic functioning: heart rate and blood 
pressure. Although these contradictory results may be due to the small number of subjects, they 
are also compatible with a modest effect on heart rate and blood pressure. All in all, sAA might be 
a more sensitive and stable marker for autonomic functioning than heart rate and blood pressure, 
as it is less influenced by confounding factors like posture and exercise (Nater et al., 2007). The 
t-Value Mean difference 
(TD – placebo)
95% CI (lower-upper) p-value
sAAt3 -3.29 -1.69 -2.91 to -0.48 0.013*
cortisolt3 -0.06 -0.03 -1.28 to 1.22 0.95
Δt3-t1 VAS-anxiety -0.78 -7.75 -31.35 to 15.85 0.46
Δt3-t1 POMS 0.16 -0.63 -8.89  to 10.14 0.88
Δt3-t1 heart rate -0.77 -5.88 -24.03 to 12.28 0.47
Δt3-t1 systolic BP -0.54 -4.75 -25.43 to 15.93 0.60
Δt3-t1 diastolic BP -2.04 -6.00 -12.95 to 0.95 0.08
Paired-samples t-test analyses; for both groups n=8. * means that the p-value is statistically significant. sAA = salivary 
alpha-amylase; TD = tryptophan depletion; VAS-anxiety = anxiety levels measured with a visual analogue scale; 
POMS = total scores of the Profile of Mood States; BP = blood pressure; t1 = 1500h, just before the preparation phase; 
t3 = 1610h, just after the public speaking challenge.
Table 1 Relative increases of sAA and cortisol (t3) and Δt3-t1 mood and anxiety scores in response 







TD procedure may have decreased the effects of public speaking on sAA concentrations as sAA 
contains the amino-acid TRP which is depleted. Nevertheless, the TD group showed significantly 
larger sAA increases as compared to the placebo group. 
We did not find an effect of TD on anxiety in response to the public speaking challenge. 
This finding is in agreement with Argyropoulos et al. (2004). However, Argyropoulos et al. did find 
effects of TD on anxiety using an autobiographical script. Such a script may be more specific for 
generalized social anxiety than public speaking is. 
To the best of our knowledge, this is the first study to describe the effects of TD on sAA 
and also the first TD study in gSAD with the assessment of neuroendocrine parameters. The 
TD procedure induced a profound decrease of TRP and the TRP/LNAA ratio in the TD group. 
However, in the control group the TRP/LNAA ratio was also decreased with 46.3%, which may 
be related to the lack of effect seen on the behavioural measures. Strength of the study is that we 
only included patients with pure gSAD and without medical disorders to rule out the possibility of 
confounding effects of comorbid disorders on the neuroendocrine data. 
In conclusion, the present study shows that in successfully SSRI-treated gSAD patients 
the stress of public speaking during TD induces higher sAA responses compared to the placebo 
condition, but has no effect on the HPA-axis. This suggests that in gSAD there is a vulnerability of 
the ANS more than the HPA-axis, which seems to be mediated by the serotonergic system.
Because of the small number of subjects this study needs replication in a larger group. 
Besides, future investigations should be directed at the specificity of these findings for gSAD, 
and of the TD effects in gSAD patients who were treated with cognitive behavioural therapy or 
noradrenaline reuptake inhibitors. Implications for the future are that, given the involvement of 
the ANS in gSAD, treatment studies should be directed at the ANS and HPA-axis rather than the 
HPA-axis alone.
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The effects of female reproductive hormones 
in generalized social anxiety disorder













Objective: Although generalized social anxiety disorder (gSAD) is more prevalent in women, the 
role of female reproductive hormones in gSAD has never been investigated. Therefore our aim was 
to make a first inventory of the influence of female reproductive hormones on gSAD symptoms. 
Method: Female patients with gSAD who had previously participated in our research projects in 
the University Medical Center Utrecht and the Leiden University Medical Center were recruited. 
A self-report survey with questions on the influence of menarche, the periods of the menstrual 
cycle, oral contraceptive use, pregnancy, lactation, postpartum period and menopause on gSAD 
symptoms was returned by 46% of 140 women suffering from gSAD. Non-parametric statistical 
tests were used to analyze the data. Results: A subgroup of patients reported an influence of female 
hormonal cycle on gSAD symptoms. In this subgroup, statistical differences were found for the 
menstrual cycle and pregnancy. In the premenstrual period, patients reported more severe gSAD 
symptoms. During pregnancy symptoms decreased, but postpartum symptom severity returned 
to the same levels as before pregnancy. Conclusions: A subgroup of women with gSAD seemed 
vulnerable for the influences of gonadal hormones. Prospective research in women with gSAD, in 
which the gonadal hormones are assessed, is warranted. 
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Introduction
Social Anxiety Disorder (SAD) is one of the most common psychiatric disorders. In a review of 
European community studies, a lifetime prevalence of 3.9 to 13.7 % for SAD according to DSM-
IV criteria was found. Moreover, the prevalence estimates were generally higher in women than 
in men (Fehm et al., 2005). Two subtypes can be distinguished: specific SAD and generalized 
SAD (gSAD) (DSM-IV-TR). The onset of gSAD is often in puberty and the symptoms of gSAD 
might be more severe in women (Keller, 2003; Wittchen and Fehm, 2003). Taken together, these 
findings might suggest that the gonadal hormones influence the onset and course of gSAD. This 
hypothesis is supported by literature on gonadal hormones and anxiety. The gonadal hormones 
estrogen and progesterone regulate the female hormonal cycle: menarche, menstrual cycle, 
pregnancy, postpartum period, lactation, and menopause. They also affect neurotransmitter 
systems that are associated with anxiety, such as the dopaminergic, serotonergic, and GABAergic 
system (for a review: Weinstock, 1999). Furthermore, the female hormonal cycle affects the 
course and severity of several symptoms of anxiety. Healthy women experienced an increase 
in anxiety symptoms during the third trimester of pregnancy (Rofe et al., 1993). Premenstrual 
increase of anxiety symptoms was reported in women with anxiety disorders, such as generalized 
anxiety disorder (GAD) and panic disorder (PD) (Hsiao et al., 2004; Brambilla et al., 2003). 
Finally, premenstrual dysphoric disorder and anxiety disorders are highly comorbid conditions 
(Hsiao et al., 2004).
In gSAD, the influences of female gonadal hormones on anxiety symptoms have never 
been investigated. The aim of the research described in this article was to explore whether there 
is an influence of the gonadal hormones on social anxiety and avoidance in women with gSAD. 
Therefore, we made a retrospective inventory of the course of gSAD symptoms during the 
female hormonal cycle. Based on the literature in other anxiety disorders, we hypothesized that 
premenstrually and in the last trimester of the pregnancy the levels of anxiety are higher.
Materials and methods
Participants and procedures
Participants were women over 18 years of age, with gSAD according to DSM-IV criteria, as 
confirmed with the MINI Plus 5.0.0 (Van Vliet and De Beurs, 2007). Comorbidity, contraception, 
and hormonal replacement therapy were allowed. Exclusion criterion was an endocrinological 
disorder of any kind. Patients who did not have a menstruation period for the past year or more 
were considered postmenopausal.
Female patients with gSAD who had previously participated in our research projects 
in the University Medical Center Utrecht (UMCU) and the Leiden University Medical Center 
(LUMC) were recruited. 







to ask their permission to call them for participation in the study. We used a directory of old 
addresses, because these patients did not receive treatment in the UMCU at the time of this study. 
Reminders were sent out to non-respondents. Patients who returned the permission form were 
called. We explained the procedures and asked if they wanted to participate. Then the survey was 
sent. In the LUMC, 44 women who participated in research or were treated for gSAD, were asked 
to participate during one of their visits. The survey was either given or sent to the patients. 
The study was approved by the Medical Ethical Committees of the UMCU and LUMC. 
All subjects gave written informed consent prior to inclusion in the study. 
Survey
Patients received a self-report survey with questions regarding demographic data and the effects 
of the female hormonal cycle on social anxiety and avoidance. The phases that were studied were 
menarche, the periods of the menstrual cycle, oral contraceptive (OC) use, pregnancy, lactation, 
postpartum period, and menopause. For each phase the first question was on the influence of 
this particular phase on symptoms of social anxiety and of social avoidance. This question could 
be answered by  “yes” or  “no”. If the answer was “yes” on this question, they were asked to score 
the levels of social anxiety and avoidance retrospectively from 0 to 10 for that particular phase. 
Patients were asked to fill in the questions on the menstrual cycle if they had a regular cycle of 24 to 
32 days and only for the time periods in which they had a natural menstrual cycle, without the use 
of oral contraceptives. Week 1 was considered the menstruation period, week 2 the late follicular 
phase, week 3 the early luteal phase, and week 4 the premenstrual phase. Questions on pregnancy 
and postpartum period were directed to the time before pregnancy, the first trimester, the second 
trimester, the third trimester, and the postpartum period. 
Statistics
Descriptive statistics were used for patient characteristics and for some outcome parameters. 
Statistical analyses were performed only on data of patients who reported an influence 
of the female hormonal cycle on symptoms of social anxiety and avoidance, and on current social 
anxiety and avoidance scores. These were categorical data. We used non-parametric statistics to 
analyse the data to avoid the normality assumption. Spearman’s Rank Order Correlation (rho) was 
performed to explore the relationship between the age of menarche and age of onset of gSAD. A 
Friedman Test was conducted to compare scores on social anxiety and avoidance across different 
time periods per phase. The Wilcoxon Signed Ranks Test was done for the comparison of social 
anxiety and avoidance as posthoc analysis for the significant outcome variables of the Friedman 
Test. This test analyses the direction and the relative magnitude of the differences within pairs.
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We sent a letter to 96 female patients with gSAD from the UMCU with information and to ask 
for permission to call them. Twenty-nine patients (30%) returned the form. They were called and 
received a survey. Twenty-seven patients (93%) completed the survey. At the LUMC, 44 female 
patients were asked to participate during a treatment or research visit. All patients volunteered and 
37 (84%) returned the survey. Overall, 64 completed surveys (46%) were received.
Patient characteristics
The mean age of the patients was 42.0 years (± 11.7; range 21-63 years). The mean age of onset for 
gSAD was 15.1 years (± 8.4). The delay from the age of onset until the diagnosis gSAD was 22.6 
years (± 14.0). Eighty-six percent of the patients received treatment for gSAD during their life, 
and 45% are currently being treated. A positive family history for gSAD was reported in 50% of 
the patients. Many patients (75%) were part-time or full-time employed. The remaining 25% were 
unemployed (14%), incapable of working (3%), retired (3%), or student (5%). Level of education 
was divided in 3 groups: 24% had a low educational level (10 years or less), 43% had a medium 
educational level (10-14 years), and 33% had a high educational level (more than 14 years).
The mean current gSAD symptoms on a scale of 0-10 of the entire sample in each area of 
work, social life, and family life were compared. It appeared that there was a statistically significant 
difference in social anxiety (p < 0.001, χ2 = 73.2, df = 2, n = 61) as well as avoidance (p < 0.001, 
χ2 = 62.3, df = 2, n = 61) in these three areas. Social anxiety and avoidance are highest in social 
life and lowest in family life. There was no significant difference in social anxiety and avoidance 
between work situations and social life (p = 0.8; p = 0.7), but both were significantly higher than 
the symptoms in family life (p < 0.001 in all cases). 
Menarche and age of onset
We found no correlation between age of menarche and age of onset gSAD (r = -0.01, n = 63, p = 
0.9).
Influence of female hormonal phase on social anxiety and avoidance
Most patients did not report any influence of menarche, menstrual cycle, OC use, pregnancy, 
and lactation. However, most patients did notice any influence of the postpartum period and 









Menarche (n=64) Menstrual cycle (n= 51) OC use (n=50) Pregnancy (n=41)
soc.anx. soc.avoi. soc.anx. soc.avoi soc.anx. soc.avoi soc.anx. soc.avoi.
Yes 13% 8% 45% 35% 12% 14% 41% 41%






Lactation (n=30) Menopause (n=13)
soc.anx. soc.avoi soc.anx. soc.avoi soc.anx. soc.avoi
Yes 56% 53% 3% 7% 69% 62%
No 44% 47% 97% 93% 31% 38%
Table 1 Influences of female hormonal cycle on gSAD symptoms
Note: Percentages of patients who did or did not report an influence on the symptoms of social anxiety (soc.anx.) 
and avoidance (soc.avoi.).
Social anxiety                  (n=23) Social avoidance                  (n=18)
Week 1 Week 2 Week 3 Week 4 Week 1 Week 2 Week 3 Week 4
Week 1 - - - - - - - -
Week 2 p=0.02* - - - p=0.010* - - -
Week 3 p=0.772 p=0.005* - - p=0.532 p=0.016* - -
Week 4 p=0.002* p=0.000* p=0.000* - p=0.015* p=0.001* p=0.002* -
Table 2 Statistical differences during the 4 weeks of the menstrual cycle
Note: P-values of the post hoc analysis with the Wilcoxon Signed Rank Test on the retrospective social anxiety and 
avoidance scores in the different weeks of the menstrual cycle. Week 1 represents the menstruation, week 2 the late 
follicular phase, week 3 the early luteal phase, and week 4 the premenstrual phase.
Figure 1 The mean social anxiety and avoidance scores (0-10) during the menstrual cycle, as obtained from the 
patients who reported an influence of the menstrual cycle on social anxiety and avoidance.
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Table 3 Statistical differences before, during, and after the 1st and 2nd pregnancy
Social anxiety 1st pregnancy (n=12)
BP Trim 1 Trim 2 Trim 3 PPP
BP - - - -
Trim 1 p=0.022* - - - -
Trim 2 p=0.005* p=0.040* - - -
Trim 3 p=0.003* p=0.054 p=0.339 - -
PPP p=0.301 p=0.016* p=0.005* p=0.005* -
Social avoidance 1st pregnancy (n=10)
BP Trim 1 Trim  2 Trim 3 PPP
BP - - - - -
Trim 1 p=0.036* - - - -
Trim 2 p=0.011* p=0.071 - - -
Trim 3 p=0.007* p=0.099 p=0.713 - -
PPP p=0.889 p=0.167 p=0.090 p=0.056 -
Social anxiety 2nd pregnancy (n=11)
BP Trim 1 Trim 2 Trim 3 PPP
BP - - -
Trim 1 p=0.070 - - -
Trim 2 p=0.016* p=0.014* - -
Trim 3 p=0.010* p=0.010* p=0.102 - -
PPP p=0.414 p=0.072 p=0.011* p=0.007*
Social avoidance 2nd pregnancy (n=9)
BP Trim 1 Trim 2 Trim 3 PPP
BP - - - - -
Trim 1 p=0.205 - - - -
Trim 2 p=0.026* p=0.034* - -
Trim 3 p=0.017* p=0.016* p=0.059 - -
PPP p=0.279 p=0.776 p=0.221 p=0.042* -
Note: P-values of the post hoc analysis with the Wilcoxon Signed Rank Test on the retrospective social anxiety and 
avoidance scores before (BP), and during pregnancy (1st trimester = Trim 1, 2nd trimester = Trim 2, 3rd trimester = 
Trim 3), and in the postpartum period (PPP) as measured in the first and second pregnancy of the patients who 
reported an influence of pregnancy and postpartum period on social anxiety and avoidance. 
Statistical analyses were performed only on data of patients who reported any influence 
of the female hormonal cycle on symptoms of social anxiety and avoidance. We report the analyses 
of the hormonal phases in which more than 10 subjects reported these influences. This was only 
the case for the menstrual cycle and pregnancy with postpartum period. Seventy-one percent of 









A difference was found in social anxiety (p < 0.001, χ2 = 39.2, df = 3, n = 23) and avoidance (p < 
0.001, χ2 = 26.6, df = 3, n = 18) between the 4 weeks of the menstrual cycle. The symptoms of social 
anxiety and avoidance were highest in week 4 of the menstrual cycle, and significantly different 
from week 1, 2 and 3. For more details, see Figure 1 and Table 2.
Pregnancy and postpartum period
The group of patients that reported an influence of pregnancy on social anxiety and avoidance 
was not entirely the same as the group of patients that reported an influence of the postpartum 
period. We only included data of patients who reported an influence of both the pregnancy and 
postpartum period in the statistical analysis. This made it possible to compare the social anxiety 
and avoidance scores of the period before pregnancy, the three trimesters of pregnancy, and the 
postpartum period. 
We found a difference in social anxiety and social avoidance between the period before 
pregnancy, all trimesters of pregnancy, and the postpartum period for the first pregnancy (p < 
0.001, χ2 = 27.4, df = 4, n = 12; p < 0.001, χ2 = 24.2, df = 4, n = 10). The same results were seen 
for the second pregnancy (p = 0.003, χ2 = 15,8, df = 4, n = 11; p = 0.002, χ2 = 16.8, df = 4, n = 9). 
Social anxiety and avoidance were highest before pregnancy and in the postpartum period. During 
pregnancy, patients reported less severe symptoms. For details see Figure 2 and Table 3.
Figure 2. Means of social anxiety and avoidance scores (0-10) before (BP) and during pregnancy (1st trimester = 
Trim 1, 2nd trimester = Trim 2, 3rd trimester = Trim 3), and in the postpartum period (PPP) as measured in the first 
and second pregnancy of  patients who reported an influence of pregnancy and postpartum period on social anxiety 
and avoidance.
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Discussion
Most respondents did not report any influence of the female hormonal cycle on gSAD symptoms. 
However, the subgroup who did, reported more severe social anxiety and avoidance in the 
premenstrual period and, as opposed to our hypothesis less severe symptoms during pregnancy. 
In this subgroup, the vulnerability for the effects of the gonadal hormones on neurotransmitter 
systems associated with anxiety may be increased. If corroborated in further studies, it would be 
interesting to investigate whether this enhanced vulnerability is associated with fewer effects of 
treatments aimed at these neurotransmitter systems.
The literature on the influence of gonadal hormones on the course of anxiety disorders 
shows that these influences exist only in a subgroup of women. The premenstrual worsening of 
symptoms in a subgroup of women as shown in this study was also found in GAD, and obsessive 
compulsive disorder (OCD) (Hsiao et al., 2004; McLeod et al., 1993; Vulink et al., 2006; Labad 
et al., 2005; Williams and Koran, 1997). In one study on panic disorder (PD) an exacerbation of 
symptoms was also seen in the premenstrual period in some patients, whereas other studies in PD 
found no differences (Hsiao et al., 2004; Pigott, 1999; Breier et al., 1986; Kaspi et al., 1994; Stein et 
al., 1989; Cook et al., 1990; Cameron et al., 1988). The decrease of symptoms during pregnancy, as 
we found in gSAD, had previously been described in some, but not all, studies in PD (Hertzberg 
and Wahlbeck, 1999; Cohen et al., 1994; Klein et al., 1994; Altshuler et al., 1998). In OCD, the effects 
of pregnancy are not clear yet, as unchanged symptoms as well as worsening and improvement of 
symptoms were described (Vulink et al., 2006; Labad et al., 2005; Williams and Koran, 1997). 
In line with the present study, the same studies showed a postpartum increase of symptoms in 
a subgroup of OCD patients (Vulink et al., 2006; Labad et al., 2005; Williams and Koran, 1997). 
There are also some limitations of the present study to discuss. As a result of the self-
report survey and the retrospective nature of this study, the results are likely to be affected by 
a significant recall bias. However, in the absence of prospective studies, these retrospective data 
provide a first impression of the nature and extent of the influences of gonadal hormones in 
gSAD. Furthermore, no data were collected on the comorbidity between gSAD and premenstrual 
syndrome and prementrual dysphoric disorder. Unfortunately, only 46% of the gSAD patients 
returned the surveys. This is mainly caused by the UMCU patients of whom we did not have recent 
addresses. In the LUMC group, of which we had recent addresses, the response rate was good 
(84%). However, we cannot rule out the possibility of responder bias, meaning that the women 
who believe in the influence of hormones on their gSAD symptoms or who experienced such an 
effect were more likely to respond. Our sample was not representative for the general population 
of female gSAD patients, as our respondents were prior participants in research studies in two 
university clinics. They were relatively highly educated and most of them had a job. Furthermore, 
we are not able to draw conclusions on differences in gSAD symptoms in OC use, lactation, and 
menopause, because of the small groups that were analyzed. Also the sub-analyses were carried 
out with very small sample sizes and therefore should be carefully interpreted. Other limitations 







hormones. For example, during pregnancy and in the post partum period life changes dramatically, 
which we did not take into account in the present study.
The clinician should take into account that there probably is at least a subgroup of female 
gSAD patients whose symptoms are influenced by fluctuations in female gonadal hormones: 
they have more severe symptoms premenstrually and less severe symptoms during pregnancy. 
Prospective studies will have to elucidate how large this proportion is and how much influence 
the gonadal hormones have on symptoms and treatment effects. Ultimately, this may lead to more 
tailor made treatments for gSAD patients.
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Social anxiety disorder (SAD) is characterized by a persistent fear of one or more social or 
performance situations in which the person is exposed to people or to possible scrutiny by others. 
Two subtypes of SAD can be distinguished: the specific (sSAD) and the generalized type (gSAD). 
In this thesis, we chose to investigate gSAD, since it is the most disabling, most severe and complete 
form, showing all aspects of social anxiety. gSAD is associated with impairment of functioning in 
social life, work and family life. An epidemiological survey in Ontario, Canada, which discriminated 
between the specific (sSAD) and the generalized type (gSAD), reported life time prevalence rates 
for gSAD of 5.9%. Treatments of choice for gSAD are serotonin reuptake inhibitors (SSRIs), 
serotonin-noradrenalin reuptake inhibitors (SNRIs) and cognitive behavioural therapy (CBT). The 
underpinnings of the neurobiology of gSAD are not clear yet, but important to investigate for the 
development of new treatments. Research in other affective disorders indicates that several hormonal 
and neuroendocrine systems might be involved, such as the serotonergic system, the dopaminergic 
system, and both branches of the stress system (the autonomic nervous system (ANS)) and the 
hypothalamic-pituitary-adrenal-axis (HPA-axis). Female gonadal hormones also influence affective 
symptoms and thus may be involved in affective disorders. The aim of this thesis is to test the role of 
these hormones and neurotransmitter systems that influence the brain for changes and investigate 
their involvement in the neurobiology of gSAD.
Generalized social anxiety disorder (gSAD) and Panic Disorder (PD) are among the most 
prevalent anxiety disorders. Although the two disorders have a different core phenomenology, with 
spontaneous panic attacks in PD, and fear of scrutiny by others in gSAD, data from epidemiological, 
pharmacotherapeutical, genetic and neurobiological studies suggest a possible overlap in the 
neurobiology of gSAD and PD. In chapter 2 we directly compared the behavioural, neuroendocrine 
and physiological effects to an acute serotonergic challenge in seven (five male and two female) 
patients with gSAD, PD and healthy controls, pair wise matched on age and sex. For this challenge 
we used the rapid intravenous administration of 0.1 mg/kg meta-chlorophenylpiperazine (m-CPP), 
a (partial) 5-HT2c receptor agonist that also possesses moderate to low affinity for other 5-HT 
receptors, as well as for (α2) adrenergic and dopamine receptors. In the study no lifetime comorbidity 
was allowed. Behavioural responses to m-CPP were measured with a Visual Analogue Scale for 
anxiety and the Panic Symptom Scale. After the challenge the occurrence of panic attacks according 
to DSM-IV criteria was assessed. Furthermore, temperature, blood pressure, heart rate, cortisol and 
growth hormone responses to the challenge were assessed. Panic attacks were significantly more 
frequently provoked in patients with PD (85%), than in patients with gSAD (14%) and to healthy 
controls (0%). Effects on the other behavioural parameters, but not on the neuroendocrine and 
physiological parameters, were significantly greater in patients with PD compared to patients with 
gSAD and controls. The difference in responses on m-CPP in PD and gSAD suggest that PD and 
gSAD are distinct psychiatric disorders on a neurobiological level. These results might also support 




In chapter 3, we examined the 123I-ß-(4-iodophenyl)-tropane (123I-ß-CIT) binding 
potential for the serotonin and dopamine transporters using SPECT imaging in patients with gSAD 
and in age and gender matched healthy controls. Twelve psychotropic medication–naïve patients 
with social anxiety disorder, generalized subtype (5 women and 7 men) and 12 healthy controls 
were studied. The SPECT scans for the serotonin transporter binding were made four hours and 
for the dopamine transporter binding 24 hours after the infusion of 123I-ß-CIT. Volumes of interest 
were constructed on MRI-coregistered SPECT scans. We found significantly higher binding 
potentials for the serotonin transporter in the left and right thalamus of gSAD patients. Patients 
had also a significantly higher binding potential for the dopamine transporter in the striatum. The 
present study provides direct evidence for abnormalities in not only the serotonergic, but also the 
dopaminergic system in patients with gSAD.
The efficacy of mirtazapine on gSAD symptoms was studied in chapter 4. Mirtazapine 
is an antidepressant that blocks α2-adrenergic autoreceptors, resulting in the stimulation of both 
noradrenergic and serotonergic pathways. It also blocks 5-HT2 and 5-HT3 receptors, and has anti-
histaminergic properties. Studies in other anxiety disorders suggest that mirtazapine has anxiolytic 
properties. We studied the effects of mirtazapine 30 mg during 12 weeks in fourteen gSAD patients 
without axis I comorbidity according to DSM-IV criteria. Twelve patients completed the study. Two 
patients (14.3%) dropped out due to side-effects. Generally, mirtazapine was well tolerated. Five 
out of 12 patients (41.7%) were classified as responders, based on a Clinical Global Improvement 
score of 1 or 2 and a reduction of the Liebowitz Social Anxiety Scale (LSAS) of 40%. The mean 
total score on the LSAS, as well as the anxiety and avoidance subscores, decreased significantly. 
This open pilot study suggests that further investigations are warranted to prove the efficacy of 
mirtazapine in generalized social anxiety disorder. The study also suggests an involvement of the 
serotonergic, noradrenergic and histaminergic pathways in gSAD.
In chapter 5 we describe both HPA-axis and ANS activity in basal non-challenging 
conditions and after 0.5 mg dexamethasone in gSAD patients, to test the reactivity of the stress-
system. To ensure stress-free sampling we collected saliva (not blood as it requires a stressful 
venipuncture) and determined cortisol and alpha-amylase (sAA), the latter a relative new marker 
of autonomic activity. Forty-three untreated gSAD patients without comorbidity were compared 
with 43 age and gender matched healthy controls in non-stressed conditions on sAA and 
cortisol after awakening, during the day (including late evening), and after a low dose (0.5 mg) 
of dexamethasone. Apart from the assessments in the morning, gSAD patients had significantly 
higher diurnal and post-dexamethasone 1600 h sAA levels. No differences between gSAD and 
controls in any cortisol measurements were found. In conclusion, in gSAD in basal, non-stimulated 
conditions and after dexamethasone, we found hyperactivity of the ANS, as measured with sAA, 
but not of the HPA-axis. This suggests a relative increased activity of the ANS but not of the HPA-
axis. The hyperactivity of the ANS is in line with the clinically observed somatic symptoms of 







In chapter 6 we studied the interplay between the serotonergic system and the stress 
system in gSAD. Two groups with nine pair wise age and gender matched gSAD patients, 
who were successfully treated with the SSRI citalopram, underwent a tryptophan depletion 
challenge (TD) or a placebo condition. A TD procedure temporarily decreases serotonergic 
neurotransmission. In order to activate the stress system, the TD/placebo challenge was 
combined with a public speaking task. We assessed ANS responses, as measured with salivary 
alpha-amylase (sAA), and HPA-axis responses, as measured with salivary cortisol, both in 
the TD and placebo condition. The TD group showed a significantly larger sAA response as 
compared to the placebo group, reflecting hyperresponsivity of the ANS in this group, whereas 
no differences were seen in cortisol responses. This suggests that in gSAD there is a vulnerability 
of the ANS and not the HPA-axis. As this was found after TD, the serotonergic system may act 
as a mediator.
Chapter 7 is the first study that aimed to explore the influence of female reproductive 
hormones on gSAD symptoms. We recruited female patients with gSAD who had previously 
participated in our research projects in the University Medical Center Utrecht and the Leiden 
University Medical Center. A self-report survey with questions on the influence of menarche, 
the periods of the menstrual cycle, oral contraceptive use, pregnancy, lactation, postpartum 
period and menopause on gSAD symptoms, was returned by 46% of 140 women suffering from 
gSAD. Most respondents reported no influence.  However, in the subgroup that did report 
such influences, statistical differences were found for the menstrual cycle and pregnancy. 
In the premenstrual period, these patients reported more severe gSAD symptoms. During 
pregnancy symptoms decreased, but postpartum symptom severity returned to the same levels 
as before pregnancy. In conclusion, a subgroup of women with gSAD seemed vulnerable for 
the influences of gonadal hormones. Prospective research in women with gSAD, in which the 
gonadal hormones are assessed, is warranted. 
Thus, in general it can be concluded that our studies showed evidence for an involvement 
of the serotonergic, dopaminergic and noradrenergic system in gSAD. In addition, we found 
evidence for the involvement of the ANS as well. No evidence was found for a role of the HPA-
axis. In a subgroup of patients the female gonadal hormones may influence the course of gSAD. 
Discussion
In this thesis, we report on our investigations regarding the involvement of several 
neurotransmitter and hormonal systems in gSAD. In this discussion we first will present a 
neurobiological model for gSAD as proposed by Tillfors (2004). This model is the most extensive 
model for gSAD thus far. We will discuss the meaning of our research findings in the context 
of this model. Finally we will discuss limitations of this thesis and suggest future directions for 




Neurobiological model for gSAD by Maria Tillfors (2004)
Tillfors describes family, twin and genetic studies that underscore the heritability of gSAD, 
although genetic factors do not nearly explain all the variance. She states that the strongest 
evidence comes from the twin studies of Kendler and collegues, which showed that in women 
genetic factors explain one third of the variance and in men a quarter of the variance (Kendler 
et al.,1992; Kendler et al., 2001). Genetic influences have also been found for temperamental 
traits that are thought to be related to the development of gSAD, such as behavioural inhibition, 
neuroticism, introversion and harm avoidance. For example, behavioural inhibition is a 
temperamental construct that is suggested to partly have a genetic basis. Physiological correlates 
of behavioural inhibition include sympathetic hyperactivity, which is interpreted as being 
associated with a lower threshold of excitability of the amygdala. Behavioural inhibition in 
children is thought to be a precursor for anxiety disorders in general and gSAD in particular 
later in life. 
There is evidence that the amygdala, in interaction with the prefrontal cortex and the 
hippocampus, is crucial in the neural circuit of anxiety (Ledoux, 1998). The amygdala monitor 
internal and external stimuli and mediate behaviours that facilitate survival. In human research it 
was found that the amygdala respond to stimuli that predict threat and are involved in mediating 
fear/anxiety states. In gSAD exaggerated amygdala activation has been the most consistent 
functional neuroimaging finding (Talarovicova et al., 2007; Birbaumer et al., 1998; Lorberbaum 
et al., 2004; Tillfors et al., 2001; Stein et al., 2002; Shah et al., 2009). After successful treatment 
for gSAD, amygdala activation was decreased during public speaking (Furmark et al., 2002). The 
fast thalamus-amygdala pathway is suggested to provide the amygdala with information of the 
external world, in order to allow a person to respond to stimuli immediately. The slower thalamo-
cortical-amygdala pathway provides the amygdala with information on objects and events 
(Ledoux, 1998). Visceral afferent information ascents from the brainstem and the hypothalamus. 
The reciprocal interaction with the hippocampus and related regions, allows the amygdala to 
incorporate information such as contextual analyses as well as an individual’s prior experience 
(memory). This in turn will allow emotions to be triggered by fearful memories. Finally, input from 
the ventromedial prefrontal cortex is suggested to modulate emotional reactivity via inhibitory 
influences on the amygdala. The amygdala mediate autonomic, neuroendocrine, and skeletal 
motor responses subserving different expressions of anxiety and fear. Projections to the striatum 
are thought to control avoidance and approach behaviour. The amygdala coordinate the actions 
of the autonomic and endocrine systems by means of direct connections to the hypothalamus 
(Talarovicova et al., 2007). Projections to the lateral hypothalamus (via the brainstem) control 
sympathetic nervous system activation and projections to the paraventricular hypothalamus and 
the bed nucleus of the stria terminalis control the release of neuroendocrine hormones such as 
gonadal and adrenocorticol hormones. Amygdaloid neurons project directly to the modulatory 
cholinergic, dopaminergic, noradrenergic, and serotonergic systems (Talarovicova et al., 2007; 








Serotonin is a wide range regulatory neurotransmitter that is present in the brain and other 
parts of the body. It has an important role in the amygdala-based fear conditioning pathways, 
which is described in the above section. Thus, modulation of the serotonergic system influences 
noradrenergic activity, the release of CRH and modifies defense/escape behaviours (Stein et 
al., 2002). Personality traits related to anxiety are associated with the serotonergic system as 
is shown in research on the meaning of polymorphisms in the serotonin transporter gene 
regulatory region (5-HTTLPR), which has two variants. The short allele is associated with 
neuroticism and harm avoidance (Lesch et al., 1996). Other findings are that human subjects 
with one or two copies of the short allele exhibit greater amygdala neuronal activity as measured 
with fMRI responses to pictures of frightened or angry faces (Hariri et al., 2002). Furthermore, 
subjects with a short allele show a stronger coupling between amygdala and prefrontal cortex 
fMRI responses to aversive pictures. The prefrontal cortex can act to suppress the amygdaloid 
output (Heinz et al., 2005). The presence of the short allele in gSAD patients was associated with 
elevated trait anxiety and depression scores, with a tendency also for neuroticism, and with 
enhanced excitability of the right amygdala when speaking in public (Furmark et al., 2004). 
Nevertheless, no genetic linkage to the serotonin transporter was found in gSAD (Stein et al., 
1998). This may indicate a modifying role of 5-HTTLPR polymorphisms in gSAD. Apart form 
studies on the genetics of gSAD, also medication, challenge and neuroimaging studies have 
been performed in gSAD. The efficacy of selective serotonin reuptake inhibitors (SSRIs), the 
results of serotonergic challenges and the finding of reduced binding of the 5HT1A-receptor in 
the amygdala also suggest the involvement of the serotonergic system in gSAD (Ipser et al., 2008; 
Hollander et al., 1998; Tancer et al., 1994; Lanzenberger et al., 2007).
Results of this thesis
Our studies added evidence for the involvement of the serotonergic system in gSAD and make the 
hypothesis of Tilfors (2004) on the role of altered serotonergic function in gSAD more specific. 
The results of our challenge study with meta-chlorophenylpiperazine (m-CPP) (chapter 2) might 
reflect hypersensitivity of the 5HT2C-receptor in gSAD compared to controls and furthermore 
show that panic disorder and gSAD are distinct psychiatric disorders on a neurobiological level. 
The hypersensitivity of this receptor might be the result of decreased serotonin activity. We also 
found increased binding patterns to the serotonin transporter in the thalamus in gSAD with a 
123I-β-(4-iodophenyl)-tropane SPECT scan. This might be the result of decreased extracellular 
serotonin levels near the transporter, allowing 123I-β-CIT to bind with higher density or perhaps 
the increased binding to the serotonin transporter reflects higher numbers of the serotonin 
transporter in the thalamus and results in a lowering of extraxcellular serotonin.
Based on our study results we hypothesize that gSAD is associated with decreased serotonin 
activity, which also is concordant with studies indicating that SSRIs are effective in the treatment 
of gSAD. According to the theory of Tillfors, decreased serotonergic controle probably also 




decreased serotonergic control of the stress system leads to an increased stress response. The 
involvement of the thalamus as we reported in our study, suggests alterations in the perception of 
the external world in gSAD, and probably is associated with the experience of the external world 
as more threatening and scrutinizing.
Dopamine
Research has been done on the dopamine D4-receptor gene and the temperamental trait novelty 
seeking, which is a central feature of behavioural inhibition. An association was found between the 
longer allele of polymorphic exon III repeat sequences of the D4-receptor and high levels of novelty 
seeking, probably reflecting decreased receptor sensitivity (Ebstein et al., 1996; Benjamin et al., 
1996; Ebstein et al., 1997; Noble et al., 1998; Ono et al., 1997; Strobel et al., 1999). Low extraversion 
(~intraversion) was associated with single nucleotide polymorphisms (SNPs) within the COMT 
gene. Furthermore, Rowe et al. reported an association between a polymorphism in the dopamine 
transporter gene and SAD in children (Rowe et al., 1998).
Li (2008) described that the brain regions that seem to be involved in gSAD, such as the 
amygdala, thalamus, prefrontal cortex and striatum, are densely innervated not only by serotonergic 
but also by dopaminergic neurons. In this article the hypothesis was formulated that impaired striatal-
thalamic filtering of information relevant for social evaluation and an excessive conditionability of 
striatal-amygdalal circuits may play a central role in the pathophysiology of gSAD. 
Several studies indicated that dopamine is involved in the neurobiology of gSAD, as was 
described in chapter 3 of this thesis in more detail. The involvement of the dopaminergic system in 
gSAD was first suggested by the increased prevalence of gSAD in Parkinson’s disease (Stein et al., 
1990). Parkinson’s disease is characterized by striatal dopaminergic hypofunction. Not only was the 
prevalence of gSAD very high (50%) in Parkinson’s disease, it also appeared that anxiety symptoms 
precede the symptoms of Parkinson’s disease (Kummer et al., 2008). Another study showed a lower 
level of homovanillic acid, a metabolite of dopamine, in the cerebrospinal fluid (Johnson et al., 
1994). Also the efficacy of MAOIs is compatible with the involvement of the dopaminergic system. 
Direct evidence of the dopaminergic involvement in gSAD has been shown in a few neuroimaging 
studies, in which decreased binding of the dopamine transporter and decreased binding of the D2-
receptor was found (Tiihonen et al., 1997; Schneier et al., 2000). 
Results of this thesis
The results of our study with 123I-β-CIT SPECT in psychotropic medication-naïve patients 
with gSAD also supports the role of the dopaminergic system, as we found a significantly 
higher binding potential for the dopamine transporter in the striatum. In other papers such a 
relationship could not be demonstrated. Tiihonen and colleagues (1997) and, recently, Schneier et 
al. (2009), published opposite findings. However, the study of Tiihonen et al. suffered from some 
methodological shortcomings as was explained in chapter 3 (Tiihonen et al., 1997). In the study 
of Schneier et al., the authors tried to unravel the dopaminergic involvement in gSAD by studying 







and SPECT scans (Schneier et al., 2000). Apart form the fact that they did not exclusively include 
psychotropic medication-naïve patients, which they mentioned in their discussion, they also did 
not exclude patients with psychiatric comorbidity. Furthermore, they group wise matched on age 
and gender in stead of the pair wise matching we did. With respect to the dopamine transporter 
availability in the striatum our study is the one with the least confounders.
 The increased binding we found of 123I-β-CIT to the dopamine transporter in the striatum 
might be the result of decreased extracellular dopamine levels near the transporter, allowing 123I-β-
CIT to bind with higher density, or the lower dopamine levels to be the result of higher numbers 
of dopamine transporters in the striatum. This might be in accordance with the reduced neural 
activation in the striatum that was found in a study in which gSAD patients and controls underwent 
a fMRI while performing a implicit sequence learning task (Sareen et al., 2007). 
Our study confirms the theory of Tillfors (Tillfors, 2004), which states that the 
dopaminergic system is involved in the neurobiology of gSAD. Combining the results of the 
above described studies, we hypothesize a decreased dopaminergic functioning in gSAD, which 
is concordant with the increased prevalence of gSAD in Parkinson’s disease. This probably is 
also compatible with the increased prevalence of alcoholism in patients with gSAD, since the 
decreased activity of dopamine as a result of long term use of alcohol is seen as a maintaining 
factor in alcoholism. The acute administration of alcohol leads to increased dopaminergic 
neurotransmission (Soderpalm et al., 2009). According to the model of Tillfors, the involvement of 
the striatum might be associated with the avoidance of social situations, which is a feature of gSAD. 
Stress system
The stress system involves the hypothalamic-pituitary-adrenal axis (HPA-as) and the Autonomic 
Nervous System (ANS). Stress initiates the release of corticotrophin releasing hormone (CRH), 
which potentiates the stress response by organizing the ANS response and the HPA-axis response. 
Thus both branches of the stress system are activated in times of stress. Both branches have been 
studied in gSAD, albeit separately and not in the same study. 
Stress system: Hypothalamic Pituitary Adrenal Axis (HPA-axis)
Research on the HPA-axis in gSAD showed that thus far, no HPA-axis dysfunctions in basal non-
stress, conditions could be found, as measured with 24h-urine, diurnal salivary cortisol curves and 
urinary cortisol after dexamethasone suppression (Potts et al., 1991; Uhde et al.,1994; Martel et al., 
1999). However, some studies, but not all, reported increased cortisol responses to stress (Martel et 
al., 1999; Condren et al., 2002; Furlan et al., 2001; Roelofs et al., 2005; Roelofs et al., 2009). Roelofs et 
al. also found that increased cortisol responses were significantly correlated to the increase in social 
avoidance behaviour as measured by the approach-avoidance task (Roelofs et al., 2009). 
Results of this thesis
In the study described in chapter 4 we found no evidence for dysfunctions of the HPA-axis, during 




suppression, based on cortisol saliva assessments. However, other studies described above showed 
a hyperreactive HPA-axis in response to a psychosocial challenge. So it might be that HPA-axis 
abnormalities in gSAD only occur in situations related to a stressor for which sufferers of gSAD 
are vulnerable.  
Stress system: Autonomic Nervous System
The involvement of the noradrenergic system and the ANS is to be expected if one observes the 
symptoms of gSAD. The efficacy of serotonin-noradrenalin reuptake inhibitors (SNRIs) implies that 
noradrenergic dysfunction is associated with gSAD. Previous studies on the noradrenergic system 
and the ANS in gSAD were done by for example measuring plasma noradrenaline levels, heart rate, 
and blood pressure. (Stein et al., 1994; Grossman et al, 2001; Gerlach et al., 2003; Laederach-Hofmann 
et al, 2002). Abnormalities found in one study often could not be replicated in another (Ipser et al., 
2008; Stein et al., 1992; Bouwer and Stein, 1998). However, major drawback in all these studies was 
the stress accompanying the sampling procedure (e.g. venipuncture) and the autonomic measures 
such as heart rate and blood pressure that are easily influenced by many factors (e.g. posture). These 
factors may well be responsible for the contradictory results. 
Results of this thesis
In chapter 4 we described a pilot study with mirtazapine 30 mg, which was effective in 41.7% of the 
patients. These results might indicate that dysregulations of the noradrenergic and serotonergic 
system in gSAD are the substrate for the efficacy of mirtazapine.
In chapter 5 we describe a study in which we investigated the ANS function in gSAD in 
basal non-stressed conditions. We investigated the sAA awakening response, the diurnal curve 
and a low dose (0.5 mg) dexamethasone suppression test in gSAD. Even though we sampled in 
non-stressed conditions, sAA levels were almost twice as high in gSAD patients as compared to 
the control subjects. This is a remarkable finding even more so because it shows the imbalance 
between the HPA-axis and ANS in gSAD.
Gonadal hormones
There are no studies that report on the influence of female gonadal hormones on gSAD symptoms 
as yet. Since the onset is often at puberty, and more women are affected and more severely than 
men, it might be expected that these hormones have an influence on gSAD.  
Results of this thesis
In chapter 7 we report on the results of our retrospective inventarisation of the influences of female 
hormonal phases on social anxiety and avoidance in female gSAD patients. Most women did not 
report any influence of the hormonal phases on gSAD symptoms. A subgroup of women however, 
reported that gSAD symptoms increased premenstrually and decreased during pregnancy. This 
possibly might indicate that a subgroup of gSAD women is vulnerable for the influences of gonadal 








In this thesis we explored the role of several hormonal and neurotransmitter systems likely to 
be involved in gSAD. Just because of this explorative approach the study of each of the systems 
remained rather superficial. This is a limitation of this thesis as it restricts the possibility 
to draw definitive conclusions. However, we think this approach is justified because, as we 
discussed already in the introduction, the neurobiology of gSAD is largely a terra incognita. 
Most limitations of the separate studies were already discussed in the corresponding chapters. 
We will not repeat them here. However, some additional remarks must be make in this final 
chapter. In chapter 2 we describe a m-CPP challenge. As we know now, a m-CPP challenge 
is not a pure serotonergic challenge, which make the results more difficult to interpret. It is 
known to be a (partial) 5-HT2C receptor agonist that also possesses moderate to low affinity 
for other 5-HT receptors, as well as for (α2) adrenergic and dopamine receptors. Therefore 
the effects of m-CPP could also partly be the effect of the influence on the adrenergic or 
dopaminergic receptors. In chapter 4 we did a mirtazapine pilot study. This study was not 
blinded and not placebo-controlled. Therefore these results are preliminary. We cannot rule 
out the possibility that the effects of mirtazapine in this study are predominantly a placebo 
effect. The results have to be replicated in a double blind, placebo-controlled trial in order to 
draw more definite conclusions. In chapter 5 and 6 we studied HPA-axis functioning. We took 
the circadian rhythm of cortisol in account, but not the pursatile release of cortisol, which 
could have influenced our results. Cortisol binds for 95% to large proteins, mostly cortisol 
binding globulin (CBG) and albumine. Only the 5% free cortisol is thought to be biologically 
active. Free cortisol enters saliva by passive diffusion, which means that the fraction of free 
cortisol is measurable in saliva. Thus a limitation is that in our studies we only measured the 
fraction of free cortisol in saliva which accurately reflects the free cortisol fraction in the 
blood, but does not reflect the total cortisol levels in the blood. In chapter 6 we used a public 
speaking challenge combined with a tryptophan depletion test. With the public speaking 
challenge we meant to evoke specifically social anxiety. However, it might be the case that this 
is not the best challenge to evoke social anxiety, as was shown in a tryptophan depletion study 
in which social anxiety was more severe during the reading of an autobiographical script than 

















In this thesis we found evidence of the involvement of serotonin, dopamine, and noradrenaline/
ANS, but not the HPA-axis, in the neurobiology of gSAD. We hypothesize that serotonin and 
dopamine function is decreased in gSAD, that there is hyperfunctioning of the ANS, and that 
HPA-axis function is not concordant with the ANS activation, as we saw in basal conditions, and 
in stress conditions following manipulation of the serotonergic system. We also think that there are 
indications that the female gonadal hormones also have a modulatory role in gSAD in a subgroup 
of women. This exploration of the neurobiology of gSAD leads to the conclusion that a variety 
of brain systems are involved in gSAD in a complex way. These results expand the model as was 
proposed by M. Tillfors in 2004.
With the exception of the HPA-axis and the ANS, we did not study the way in which the 
neurotransmitter (serotonin, dopamine and noradrenaline) systems we studied interact in 
gSAD. However, several studies report on the interaction between these systems, although not in 
gSAD. The influence of serotonin on the HPA-axis has been studied several times in depression, 
showing that under conditions of chronically elevated corticosteroid concentrations, serotonergic 
neurotransmission is impaired (Van Praag, 1996; Meijer and De Kloet, 1998). Polymorphisms of the 
serotonin transporter affected the HPA-axis stress response to painful stimulation in newborn babies 
(Mueller et al., 2009). In a review of Lanfumey the reciprocal interactions between the HPA-axis and 
the serotonergic system are well described. The hippocampus seems to play a particular role in the 
serotonergic-HPA-axis interactions in response to stress (for a review see Lanfumey et al., 2008). 
The interplay between noradrenaline and serotonin  depends on the region and receptors that are 
activated as was described by Demling et al. (2009). Animal research has shown that manipulation 







autoinhibition was found that they were not able to activate autonomic target organs in response 
to environmental challenges (Audero et al., 2008).  In mice lacking serotonin reduced heart rate 
and respiration was found (Alenina et al., 2009). In chapter 5 we described a tryptophan depletion 
study, combined with a public speaking challenge, in gSAD patients who were responders to 
SSRI-treatment. In this study two groups of gSAD patients were tested, one group underwent 
the tryptophan depletion, the other group a control condition. In this study no differences were 
seen in cortisol responses following the public speaking challenge after serotonergic manipulation. 
Importantly, we did find hyperresponsiveness of the ANS to stress after serotonergic manipulation 
in medicated gSAD patients.
These studies show that the two branches of the stress system do not act in concert in gSAD, both 
in basal and in stress conditions, which is a remarkable finding. The results are in line with the 
hyperarousal that is part of the phenomenology in gSAD. Therefore ANS hyperfunction may play 
an important role in the neurobiology of gSAD, although the specifity of these results for gSAD has 
yet to be determined. Our finding of basal hyperfunction of the ANS confirms the hypothesis of 
Tillfors (2004) who postulated that the hyperfunction could be associated with a lower threshold 
of excitability of the amygdala. These findings might also have implications for the efficacy of 
pharmacological agents. As yet, no clinical trials are published that compare the efficacy of SSRIs 
with agents that also influence the noradrenergic system.
Future research
Future research may focus on the specificity of the imbalance between the HPA-axis and the ANS 
system in gSAD. Therefore the HPA-axis and ANS should be studied in concert in other psychiatric 
disorders. In addition, we think that the dopaminergic system should be further investigated as 
well as the interactions between the several brain systems. It would be of interest to also study these 
systems in children that suffer from gSAD, or are at risk for the development of gSAD, in order to 
get more insight in the imbalances at the moment that the illness becomes manifest, before all kinds 
of compensatory mechanisms of the brain have become active. Finally, our suggestion for a next 
step in pharmacological research in gSAD is to investigate agents that influence predominantly 
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In dit proefschrift wordt onderzoek beschreven naar de betrokkenheid van diverse neurobiologische 
systemen in de hersenen bij gegeneraliseerde sociale angststoornis. 
In hoofdstuk 1 wordt het proefschrift ingeleid. Sociale angststoornis (SAD)1, ook wel 
sociale fobie genoemd, wordt gekenmerkt door een aanhoudende angst voor sociale situaties 
waarin de persoon in contact komt met mensen of mogelijke kritiek van anderen. Voorbeelden 
van dit soort situaties zijn: het voeren van een gesprek, het bijwonen van een vergadering, het 
geven van een presentatie, op visite gaan, koffie drinken in gezelschap, telefoneren in gezelschap 
en het geven van de eigen mening of kritiek. Blootstelling aan de gevreesde situaties lokt angst uit, 
die vaak gepaard gaat met lichamelijke angstverschijnselen zoals blozen, transpireren, trillen en/of 
hartkloppingen. De angst kan zo hevig zijn dat er een paniekaanval ontstaat. Door deze klachten 
ontstaat anticipatieangst en vermijdingsgedrag ten aanzien van de sociale situaties. De klachten 
gaan meestal gepaard met veel schaamte.  De symptomen ontstaan in het algemeen in de puberteit 
of al daarvoor. Er kunnen twee subtypen van SAD onderscheiden worden: het specifieke subtype 
(sSAD) en het gegeneraliseerde subtype (gSAD). In dit proefschrift hebben we ervoor gekozen 
het gegeneraliseerde subtype te onderzoeken, omdat dat het meest invaliderende, ernstigste en 
meest volledige type is en alle aspecten van sociale angst vertoont. gSAD is geassocieerd met 
verminderd functioneren in het sociale leven, het gezinsleven en op het werk. Een Canadese 
studie naar het voorkomen van gSAD toont aan dat gedurende het leven 5.9 % van de bevolking 
op een bepaald moment aan gSAD lijdt. Conform de Nederlandse Multidisciplinaire Richtlijnen 
bestaat de behandeling van gSAD uit cognitieve gedragstherapie (een vorm van kortdurende 
psychotherapie), medicatie, of een combinatie van beide. Als wordt gekozen voor medicatie 
zijn selectieve serotonine heropname remmers (SSRI’s) of serotonine-noradrenaline heropname 
remmers (SNRI’s) de eerst aangewezen middelen. 
De neurobiologische oorzaken van gSAD zijn niet precies bekend. Het is van belang 
deze te onderzoeken om de stoornis en het ontstaan ervan beter te begrijpen en zo ook nieuwe 
en effectieve behandelmethoden te kunnen ontwikkelen. Onderzoek naar de neurobiologie 
van andere angst- en stemmingsstoornissen toonde de mogelijke betrokkenheid van diverse 
neurotransmitter systemen in de hersenen aan. Voorbeelden hiervan zijn het serotonerge en het 
dopaminerge systeem. Serotonine en dopamine zijn neurotransmitters (boodschapperstoffen) 
die de informatieoverdracht tussen zenuwcellen verzorgen. Daarnaast is er het stress-systeem, 
dat bestaat uit het autonome zenuwstelsel (ANS) en de hypothalamus-hypofyse-bijnier-as (HPA-
as), en dat neurotransmittersystemen in de hersenen moduleert. Bij stress wordt het hormoon 
CRH (corticotropin releasing hormone) in de hersenen afgegeven. Dit hormoon activeert zowel 
het ANS als de HPA-as.  Bij stress of gevaar zorgt het ANS ervoor dat, via de uitscheiding van 
adrenaline en noradrenaline, het lichaam in directe staat van paraatheid wordt gebracht. De HPA-





as wordt ook geactiveerd door stress, waardoor de bijnieren worden gestimuleerd tot de afgifte 
van het stresshormoon cortisol in het bloed. Verder beïnvloeden vrouwelijke geslachtshormonen 
angst en stemming en zouden dus betrokken kunnen zijn bij affectieve stoornissen. Het doel van 
dit proefschrift is om de betrokkenheid van de bovengenoemde systemen bij de neurobiologie 
van gSAD te onderzoeken.gSAD en paniekstoornis (PD) behoren tot de meest voorkomende 
angststoornissen. Hoewel ze verschillende primaire kenmerken hebben, PD wordt gekenmerkt 
door spontane paniekaanvallen en gSAD door de angst om door anderen bekritiseerd te worden, 
suggereren epidemiologische, farmacologische, genetische en neurobiologische onderzoeken 
dat beide angststoornissen elkaar op neurobiologisch gebied overlappen. In hoofdstuk 2 hebben 
we de gedragsmatige en biologische effecten van een acute serotonerge provocatietest bij zeven 
(vijf mannen en twee vrouwen) patiënten met gSAD, PD en gezonde controles direct met elkaar 
vergeleken. Deze provocatietest werd verricht door 0.1 mg/kg meta-chlorophenylpiperazine 
(m-CPP), een stof die het serotonerge systeem stimuleert, maar die ook een gering effect heeft op 
het adrenerge en dopaminerge systeem, snel in een bloedvat toe te dienen. De deelnemers hadden 
geen andere psychiatrische of lichamelijke ziekten. Na de provocatietest werd het effect op het 
angstniveau van de deelnemers gemeten en werd bepaald of er een paniekaanval was opgetreden. 
Daarnaast werden de temperatuur, de bloeddruk en de hartfrequentie gemeten en werden cortisol 
en groeihormoon in het bloed bepaald. Paniekaanvallen uitgelokt door m-CPP toediening bleken 
vaker voor te komen bij mensen met PD (85%) dan bij mensen met gSAD (14%) en gezonde 
controles (0%). De angstscores waren hoger bij patiënten met PD dan in de andere twee groepen. 
Er waren geen verschillen in de groepen wat betreft de temperatuur, bloeddruk, hartfrequentie, 
of hormoon spiegels. De eerste conclusie op basis van deze studie was dat de verschillen in 
respons op m-CPP suggereren dat PD en gSAD verschillende psychiatrische stoornissen zijn op 
neurobiologisch niveau. De tweede conclusie was dat patiënten met gSAD anders reageren op deze 
serotonerge provocatietest dan gezonde controles. Hiermee werd aangetoond dat het serotonerge 
systeem een rol speelt in de neurobiologie van gSAD. We hebben dit verder geëxploreerd in het 
onderzoek dat in hoofdstuk 3 wordt beschreven. 
In hoofdstuk 3 beschrijven we een studie waarin we de binding van 123I-ß-(4-
iodophenyl)-tropane (123I-ß-CIT) aan de serotonine en dopamine transporteiwitten met behulp 
van SPECT scans onderzochten. Bij een SPECT scan (afkorting van Single Photon Emission 
Computed Tomography) wordt gebruik gemaakt van radioactief gelabelde stoffen waardoor een 
driedimensioneel beeld gemaakt wordt. Doordat 123I-ß-CIT zich selectief bindt aan de serotonine 
en dopamine transporteiwitten kan een afbeelding worden verkregen van de hoeveelheid en 
verdeling hiervan in de hersenen. Om de binding aan de transporteiwitten voor serotonine vast 
te leggen werd 4 uur na toediening van de 123I-ß-CIT een SPECT scan gemaakt, om de binding 
aan de transporteiwitten voor dopamine vast te leggen na 24 uur. Twaalf patiënten met gSAD (5 
vrouwen en 7 mannen), die nog nooit psychiatrische medicatie hadden gebruikt en 12 op leeftijd 
en geslacht gematchte gezonde vrijwilligers werden onderzocht. We vonden hogere binding van 







verbindingsstation vormt tussen de informatie die binnenkomt vanuit het lichaam en de hogere 
hersengebieden) en een hogere binding van 123I-ß-CIT aan de transporteiwitten voor dopamine 
in het striatum (een hersenstructuur die onder andere geactiveerd is bij belonende stimuli) bij 
gSAD patiënten vergeleken met gezonde vrijwilligers. Dit onderzoek levert direct bewijs dat er 
afwijkingen zijn in zowel het serotonerge als het dopaminerge systeem bij patiënten met gSAD.
De effectiviteit van mirtazapine op de symptomen van gSAD werd bestudeerd in 
een onderzoek dat beschreven is in hoofdstuk 4. Mirtazapine is een antidepressivum dat het 
serotonerge systeem stimuleert via stimulatie van het noradrenerge systeem. Mirtazapine 
beïnvloedt ook het histaminerge systeem. Studies met deze stof bij andere angststoornissen 
suggereerden dat mirtazapine angstverlagend werkt. We onderzochten de effecten van mirtazapine 
30 mg per dag gedurende 12 weken bij veertien patiënten met gSAD zonder andere psychiatrische 
stoornis. Twaalf patiënten maakten het onderzoek af. Twee patiënten (14.3%) vielen uit omdat 
ze teveel last van bijwerkingen hadden. In het algemeen werd mirtazapine goed verdragen. Vijf 
van de twaalf patiënten werden geclassificeerd als responders op de behandeling, wat wil zeggen 
dat ze een afname hadden op de Liebowitz Sociale Angst Schaal (LSAS) van 40% of meer. De 
gemiddelde LSAS score in de hele groep patiënten nam significant af. Dit onderzoek suggereert de 
betrokkenheid van serotonerge, noradrenerge en mogelijk histaminerge systemen in gSAD.
In hoofdstuk 5 hebben we onderzoek naar zowel de HPA-as activiteit als de acitviteit van 
het autonome zenuwstelsel (ANS) beschreven bij patiënten met gSAD in basale omstandigheden 
en na toediening van 0.5 mg dexamethason. Met dexamethason kan de remming van het stress-
systeem getest worden. Om ervan verzekerd te zijn dat de verzameling van de gegevens stress-
vrij verliep hebben we speeksel in plaats van bloed verzameld waaruit cortisol en speeksel alpha-
amylase (sAA) werden bepaald. (Bloed prikken levert stress op wat ervoor zorgt dat het stress-
systeem ongewenst wordt geactiveerd. Speeksel wordt verzameld door het kauwen op een watje 
en is niet stressvol). Cortisol is een al langer bestaande maat voor HPA-as acitiviteit. sAA is een 
relatieve nieuwe marker voor het autonome zenuwstelsel. Drieënveertig onbehandelde gSAD 
patiënten zonder comorbiditeit werden vergeleken met 43 op leeftijd en geslacht gematchte 
gezonde controles op sAA en speeksel cortisol in niet-stressvolle omstandigheden, gemeten op 
verschillende tijdstippen van de dag. Aan het eind van de eerste meetdag werd dexamethason 
ingenomen, en de volgende dag werden sAA en cortisol opnieuw op 2 tijdstippen gemeten. De 
resultaten waren dat  patiënten met gSAD significant hogere sAA waarden over de dag hadden, 
zowel vóór als na toediening van dexamethason. Er werden geen verschillen gevonden tussen de 
groepen wat betreft de cortisolwaarden. Dit betekent dat bij gSAD onder basale, niet-stressvolle, 
omstandigheden hyperactiviteit van het autonome zenuwstelsel (ANS) aanwezig is. Bovendien 
hebben we gevonden dat de HPA-as activiteit niet parallel loopt aan de activiteit van het ANS, 
maar gelijk blijft aan die van de gezonde vrijwilligers. De hyperactiviteit van het ANS komt overeen 





Hoofdstuk 6 beschrijft de wisselwerking tussen het serotonerge systeem en het stress-
systeem bij gSAD. Twee groepen met negen paarsgewijs op leeftijd en geslacht gematchte patiënten 
met gSAD, die succesvol behandeld waren met een SSRI (citalopram), ondergingen een tryptofaan-
depletietest (TD) of een placeboconditie. Een TD procedure zorgt ervoor dat er tijdelijk minder 
serotonine beschikbaar is, en dus dat het serotonerge systeem minder actief is. Om het stress-
systeem te activeren werd deze TD procedure of de placebo procedure gecombineerd met een 
’public speaking task’, waarbij de deelnemer een voordracht moest houden voor een gefingeerd 
publiek. Om de stress te verhogen werd voorgewend dat deze voordracht werd opgenomen op 
video en er werd verteld dat er een beoordeling op zou volgen. In het speeksel werd sAA gemeten 
als maat voor het ANS en speeksel cortisol als maat voor de HPA-as. De resultaten waren dat de 
na de ‘public speaking task’ de TD groep een significant hogere sAA respons had dan de placebo 
groep. Dit betekent dat er sprake is van hyperresponsiviteit van het ANS in deze groep. Er werden 
geen verschillen gezien in cortisolrespons tussen de groepen. Deze resultaten suggereren dat er bij 
gSAD een ontregeling is in ANS functie en niet in HPA-as functie. Aangezien dit werd gevonden 
na een TD, betekent dat mogelijk dat het serotonerge systeem een modulerende rol speelt in de 
hyperresponsiviteit van het ANS
In hoofdstuk 7 staat een studie beschreven die tot doel had de rol van de vrouwelijke 
geslachtshormonen in gSAD te exploreren. We recruiteerden vrouwelijke patiënten met 
gSAD die voorheen hadden meegewerkt aan onze onderzoeksprojecten in het Universitair 
Medisch Centrum Utrecht en het Leids Universitair Medisch Centrum. Zesenveertig procent 
van 140 benaderde vrouwen met gSAD retourneerden de enquête met vragen over de invloed 
van menarche (allereerste menstruatie), menstruele cyclus, gebruik van orale anticonceptie, 
zwangerschap, borstvoeding, periode na de bevalling en de overgang, op gSAD symptomen. 
De meeste respondenten rapporteerden geen invloed van deze hormonale fasen op hun sociale 
angstklachten. Maar, in de subgroep van vrouwen die wel invloed hadden gerapporteerd, werden 
statistische verschillen gevonden op hun gerapporteerde angstverschijnselen gedurende de 
menstruele cyclus en de zwangerschap. In de premenstruele periode rapporteerden deze vrouwen 
ernstiger gSAD symptomen. Tijdens de zwangerschap werden de symptomen minder, maar in de 
periode na de bevalling werden de symptomen weer net zo ernstig als vóór de zwangerschap. Dus 
in een subgroep van vrouwen werd een invloed bemerkt van de vrouwelijke geslachtshormonen op 
gSAD symptomen gedurende de menstruele cyclus en de zwangerschap.
Discussie
Het resultaat van de m-CPP provocatie test in hoofdstuk 2 waarbij de patiënten met gSAD een 
sterkere reactie laten zien dan de gezonde controles is mogelijk het resultaat van verlaagde serotonerge 
activiteit. De verhoogde binding van 123I-ß-CIT aan de serotonine transporteiwitten in de thalamus in 
hoofdstuk 3 kan het resultaat zijn van verminderde serotonine niveaus rondom de transporteiwitten 







hypothese, voortkomend uit beide studies, is dat gSAD geassocieerd is met verlaagde serotonerge 
activiteit. Deze hypothese wordt onder meer gesteund door de effectiviteit van SSRI’s bij patiënten 
met gSAD.
Met betrekking tot de hogere binding van 123I-ß-CIT aan de dopamine transporteiwitten in 
het striatum in gSAD, zoals beschreven in hoofdstuk 3, gelden dezelfde verklaringsmogelijkheden 
als hierboven beschreven voor de serotonine transporteiwitten. Wij hypothetiseren dat er bij gSAD 
sprake is van verminderde dopaminerge activiteit, hetgeen bijvoorbeeld ook zou passen bij het 
toegenomen voorkomen van gSAD bij (voorafgaand aan de manifestatie van) de ziekte van Parkinson. 
Uit hoofdstuk 4, 5 en 6 kan geconcludeerd worden dat het noradrenerge systeem/ANS 
hyperactief is bij gSAD, terwijl de HPA-as functie niet afwijkt van gezonde controles. 
Uit hoofdstuk 7 kan de conclusie worden getrokken dat een subgroep van vrouwen met 












Op grond van onze conclusies komen we tot het bovenstaande hypothetische model dat 
de neurobiologie van gSAD schematisch weergeeft. Wij denken dat er sprake is van verminderd 
functioneren van zowel het serotonerge als het dopaminerge systeem, dat er sprake is van verhoogde 
activiteit van het autonome zenuwstelsel en dat de HPA-as functie niet synchroon loopt met de 
verhoogde activiteit van het autonome zenuwstelsel. We denken ook dat er aanwijzingen zijn voor 
de modulerende rol van vrouwelijke geslachtshormonen bij gSAD bij een subgroep van vrouwen.
Conclusie: de onderzoeken beschreven in dit proefschrift zijn een belangrijke aanvulling 
op de inzichten wat betreft de rol van het serotonerge en dopaminerge systeem, het stress-systeem 
bestaand uit het autonome zenuwstelsel en de hypothalamus-hypofyse-bijnier-as, en de vrouwelijke 
geslachtshormonen in de neurobiologie van de gegeneraliseerde sociale angststoornis.
117




Nu is het zover. Een moment waar ik lang naar heb uitgekeken, mijn proefschrift is af.
Mijn promotor, Frans Zitman, en copromotores, Irene van Vliet en Roel de Rijk, wil ik bedanken 
voor hun deskundige begeleiding en voor het vertrouwen dat ze in me hebben gesteld. Hierdoor 
heb ik mijn promotietraject in het LUMC kunnen voortzetten. 
Herman Westenberg wil ik bedanken voor zijn begeleiding in mijn Utrechtse onderzoeksjaren. 
Ik heb veel van hem geleerd.
Veel dank ben ik verschuldigd aan de patiënten met een sociale fobie die met zoveel volharding 
en enthousiasme hebben meegewerkt aan de onderzoeken. Zonder hun geloof in het belang 
ervan was het niet gelukt en ook lang niet zo plezierig werken geweest. ZONMW wil ik bedanken 
voor de financiële ondersteuning van een belangrijk deel van het onderzoek.
Voor het onderzoek zijn de secretaresses van het stafsecretariaat en het polisecretariaat van het 
UMC Utrecht en het LUMC onmisbaar geweest. Ik wil hen dan ook hartelijk danken voor hun 
inzet en hun begrip voor het feit dat telefoneren voor deze categorie patiënten niet eenvoudig is.
Nic van der Wee wil ik bedanken voor de samenwerking en zijn begeleiding bij de m-CPP 
studie en het SPECT onderzoek. Bovendien wil ik alle mensen die hebben meegewerkt aan 
de praktische uitvoering van het onderzoek hartelijk bedanken, zowel in het UMC Utrecht, 
als in het LUMC.  Met nadruk noem ik Arjan de Meij, Rosalinde Poortvliet, Barbara Jonker, 
Ron Holverda, Marieke de Wit, Betty Elte-de Wever en Jolanda Verhagen. Bart Mertens wil ik 
bedanken voor de statistische bijstand die hij heeft verleend, Hans van Pelt voor het verzorgen 
van de benodigde cortisol- en amylasebepalingen als hoofd van het laboratorium.
Mijn collega’s arts-assistenten en supervisoren dank ik voor de interesse, de steun en de 
mogelijkheden om de onderzoeksmomenten te scheiden van de patiëntenzorg. Roos van der 
Mast, bedankt voor je begeleiding, begrip en de mogelijkheid die je me als supervisor op de poli 
hebt geboden om aaneengesloten tijd te besteden aan het afronden van mijn onderzoek, in een 
periode dat de laatste loodjes erg zwaar wogen.
Alle onderzoekscollega’s uit het LUMC wil ik bedanken voor de prettige en inspirerende 
samenwerking. Margien, Ellen, Floriana en Marie-José, dank jullie wel voor alle hulp in de 
laatste fase.
Mijn vrienden, vriendinnen en mijn intervisiegroep wil ik bedanken voor hun warme 
belangstelling en begrip. Martijn, bedankt dat ik mocht profiteren van je ervaringsdeskundigheid. 
Simone, Julia, Rebecca en Martine, wat fijn dat ik jullie heb en dat ik bij jullie terecht kan.
Miel, bedankt voor je beschikbaarheid, rust en inzicht in de meest turbulente jaren van mijn 
leven. 
Mijn paranimfen Simone en Margien, ik ben heel blij dat jullie ook op deze dag naast me willen 
staan.
Lieve pap en mam, jullie hebben me gestimuleerd om iets met mijn talenten te doen, om 
onafhankelijk te zijn en kritisch. Ik ben jullie dankbaar voor jullie liefdevolle zorg voor de 
kinderen, waardoor het mogelijk was dit te doen.
119
Dankwoord
Lieve Rachel en Sofie, ik ben zó blij met jullie! Hoe zwaar de afgelopen periode soms ook was, 
jullie maken dat elke dag de moeite waard is.
Lieve Kees, vóór ik zwanger werd spraken we af de zorg voor de kinderen te delen. Maar ik had 
nooit kunnen denken dat ik zoveel van je zou moeten vragen (en het zijn altijd de rotklussen!) 




Mirtazapine in social anxiety disorder: a pilot study. Van Veen, J.F., Van Vliet, I.M., Westenberg, 
H.G.M. (2002). Int. Clin. Psychopharmacol. 17(6), 315-317
Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) 
in patients with generalized social anxiety disorder, panic disorder and healthy controls. Van 
Veen, J.F., Van der Wee, N.J.A., Fiselier, J., Van Vliet, I.M., Westenberg, H.G.M. (2007). Eur. 
Neuropsychopharmacol. 17(10), 637-642.
Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients 
with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. Van 
der Wee, N.J.A., Van Veen, J.F., Stevens, H., Van Vliet, I.M., Van Rijk, P.P., Westenberg, H.G.M. 
(2008). J. Nucl. Med. 49(5), 757-763.
Elevated alpha-amylase but not cortisol in generalized social anxiety disorder. Van Veen, J.F., Van 
Vliet, I.M., Derijk, R.H., Van Pelt, J., Mertens, B., Zitman, F.G. (2008). Psychoneuroendocrinology 
33 (10), 1313-1321.
Tryptophan depletion affects the autonomic stress response in generalized social anxiety disorder. 
Van Veen, J.F., Van Vliet, I.M., Derijk, R.H., Van Pelt, J., Mertens, B., Fekkes, D., Zitman, F.G. 
(2009) Psychoneuroendocrinology 34(10), 1590-1594.
The effects of female reproductive hormones in generalized social anxiety disorder. Van Veen, J.F., 
Jonker, B.W., Van Vliet, I.M., Zitman, F.G. (2009) Int. J. Psychiatry Med. 39(3), 283-295.
Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled 
study. Schutters, S.I.J., Van Megen, H.J.G.M., Van Veen, J.F., Denys, D.A.J.P., Westenberg, H.G.M. 
(2010). Int. Clin. Psychopharmacol. Accepted for publication.
The combination of paroxetine and mirtazapine in generalized social anxiety disorder – mirtazapine 
addition in social anxiety disorder -. Schutters, S.I.J., Van Megen, H.J.G.M., Van Veen, J.F., Schruers, 
K.R.J., Westenberg, H.G.M. Submitted. 
In gesprek over: Sociale Fobie. Van Veen, J.F., Van Vliet, I.M., Van Balkom, A.J.L.M. (2004) 




Frederieke van Veen werd geboren op 4 juni 1974 in Utrecht. Na het behalen van haar gymnasium 
diploma aan het College Blaucapel in Utrecht begon zij in 1992 aan de studie geneeskunde aan 
de Rijksuniversiteit van Utrecht. In 1996 deed zij een wetenschappelijke stage van een jaar naar 
‘Hormonale veranderingen bij vrouwen in de menopauze en de neiging tot agressie’ bij mevr. 
prof. dr. P.T. Cohen-Kettenis in het Academisch Ziekenhuis Utrecht. In 1997 behaalde zij het 
doctoraalexamen en na het doen van de coschappen in 1999  het artsexamen. Aansluitend werkte zij 
ruim twee jaar als arts-onderzoeker bij de angstonderzoeksgroep van de afdeling psychiatrie in het 
Universitair Medisch Centrum Utrecht, waar ze begon met het onderzoek naar de neurobiologie 
van gegeneraliseerde sociale angststoornis. Zij werd hierin begeleid door mevr. dr. I.M. van Vliet 
en prof. dr. H.G.M. Westenberg. Vanaf 2002 zette ze het onderzoek naar gegeneraliseerde sociale 
angststoornis voort op de afdeling psychiatrie van het LUMC, eerst als arts-onderzoeker en later 
als aiosko (assistent in opleiding tot specialist en klinisch onderzoeker). Ze startte in oktober 2004 
met de eerste opleidingsstage van de opleiding psychiatrie van LUMC/Rivierduinen met prof. dr. 
F.G. Zitman als hoofdopleider en mevr. prof. dr. R.C. van der Mast als waarnemend opleider. Voor 
de opleiding psychiatrie werkte ze een jaar in het LUMC en de overige jaren bij GGZ Leiden van 
Rivierduinen. Ze is momenteel werkzaam bij het Centrum Persoonlijkheidsstoornissen Jelgersma 
van GGZ Leiden en zal de opleiding psychiatrie naar verwachting in april 2011 afronden. 




ACTH  adrenocorticotrope hormone
ANS  autonomic nervous system
AUC  area under the curve
AVP  arginine-vasopressine
β -CIT  I-β-(4-iodophenyl)-tropane
BDI  Beck depression inventory
BMI  body mass index
BP  blood pressure
CAR  cortisol awakening rise
CBT  cognitive behavioural therapy
CGI  clinical global improvement scale
COMT  catechol-O-methyltransferase
CRH  corticotrophin releasing hormone
DAT  dopamine transporter
DSM  diagnostic and statistical manual of mental disorders
DST  dexamathasone suppression test
ERβ  estrogen receptor β
fMRI  functional magnetic resonance imaging
GABA  gamma-aminobutyric acid
GAD  generalized anxiety disorder
gSAD  generalized social anxiety disorder
GH  growth hormone
GR  glucocorticoid receptor
HDRS  Hamilton depression rating scale
HPA-axis hypothalamic-pituitary-adrenal-axis
5HT  5-hydroxytryptamine = serotonin
5HTP  5-hydroxytryptophan
5HTT  serotonin transporter
5HTTLPR serotonin linked polymorphic region polymorphism
LNAA  large neutral amino acid
LOCF  last observation carried forward
LSAS  Liebowitz social anxiety scale
LUMC  Leiden University Medical Center
MAO  monoamine oxidase
MAOI  monoamine oxidase inhibitor
m-CPP  metachlorophenylpiperazine
MR  mineralocorticoid receptor
MRI   magnetic resonance imaging
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Abbreviations
OC  oral contraceptives
OCD  obsessive compulsive disorder
PD  panic disorder
PET  positron emission tomography
POMS  profile of mood states
PSS  panic symptom scale
PTSD  posttraumatic stress disorder
ROI  region of interest
sAA  salivary alpha amylase
SAD  social anxiety disorder
SPECT  single photon emission computed tomography
SNRI  serotonin-noradrenaline reuptake inhibitor
sSAD  specific social anxiety disorde
SSRI  selective serotonin reuptake inhibitor
TD  tryptophan depletion
TRP  tryptophan
UMCU  University Medical Center Utrecht
VAS  visual analogue scale
VOI  volume of interest

